Loading...
Freedom of Information (FOI) NHS Lothian | Our Organisation

Request and Response Register

NOTE: 100 recent requests are displayed below. Use search to find older requests.
Freedom of Information Request Reference: 11997
Date Received: 05/10/2026
Summary:
Request in relation to medical record.
Date of Response: 05/10/2026
View Response: 11997.pdf
Freedom of Information Request Reference: 11939
Date Received: 15/09/2026
Summary:
Please could you provide the following information for each of the technology service categories listed below: 1. The name of the current supplier(s) providing this service. 2. The annual or total contract value. 3. The contract start date and the date it is due to expire or next be reviewed/renewed. Categories: • Network firewall, VPN, or perimeter security • Endpoint protection or antivirus • Network or threat detection and response (e.g. SIEM, NDR) • Email security or anti-phishing • Vulnerability management or security scanning
Date of Response: 07/10/2026
View Response: 11939.pdf
Freedom of Information Request Reference: 11932
Date Received: 17/09/2026
Summary:
I am trying to get an estimate of 2026 waiting list times for an audiology appointment in NHS Lothian.
Date of Response: 07/10/2026
View Response: 11932.pdf
Freedom of Information Request Reference: 11927
Date Received: 16/09/2026
Summary:
I would therefore be grateful if the Council could provide the following information: 1. **Feasibility work:** What feasibility work or assessment was undertaken following the 2021 motion calling for GP and primary care provision in Wallyford? Please provide copies of any relevant reports, assessments, correspondence, meeting minutes or recommendations. 2. **Decision not to proceed with the NHS site:** What reasons were provided by the NHS for deciding not to acquire, lease or otherwise make use of the site identified for an NHS facility within Area 5? Please provide any correspondence or documentation held by the Council relating to this decision. 3. **Population and GP provision assumptions:** What population projections, patient numbers, GP-to-population ratios, capacity assessments, or other assumptions were used when assessing whether a GP surgery or primary care facility in Wallyford was viable or necessary? 4. **Alternative sites and future provision:** Has the Council, NHS Lothian or any other relevant public body identified or considered an alternative site in Wallyford for a GP surgery or other primary care facility? If so, please provide details of the sites considered and the status of any proposals.
Date of Response: 07/10/2026
View Response: 11927.pdf
Freedom of Information Request Reference: 11925
Date Received: 16/09/2026
Summary:
Could you please provide me with details of any 'redeployment pool' or 'redeployment register' operated by the health board. Please also send me a copy of any formal policy regarding the operation of the pool. By redeployment pool/register, I mean any mechanism for workers whose roles are no longer required, but instead of being made redundant, continue to be employed with a view to an alternative role being found for them. Can you please provide the following: - how many employees are currently in your redeployment poll? - of these workers, please specify how many have been in the pool for; under one year, 1-2 years, 2-3 years, 3-4 years, 4-5 years, five years or more. - if a worker has been in the pool for five years or more, the total time, to the closest year, they have been in the pool. - the current monthly cost to the organisation of employing workers who are in the redeployment pool, inclusive of NI costs, pension contributions, etc.
Date of Response: 07/10/2026
View Response: 11925.pdf
Freedom of Information Request Reference: 11917
Date Received: 10/09/2026
Summary:
We would be obliged if you would provide the following information: • Confirmation that Pinnacle Roofing (Scotland) Ltd was the contractor carrying out roof works on or around the index date at Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, • Confirmation of the scope of work being carried out by Pinnacle Roofing (Scotland) Ltd, • Dates Pinnacle Roofing (Scotland) Ltd attended Western General Hospital to carry out works, • We note that a roof tile fell prior to the index accident on 6 February 2026, please provide the circumstances and details of this incident along with any investigations, maintenance, remedial works, risk assessments or safe systems of work put in place prior or subsequent to this event, • Please detail any other instances where roof tiles or other roof objects have feel from the ceiling during the contractual works being carried out by Pinnacle Roofing (Scotland) Ltd, • Please detail any investigations which have taken place prior to the index event and the incident on 6 February 2026, • Please provide details of any risk assessments or safe systems of work detailed prior to or after our client’s index accident related to the work being carried out by Pinnacle Roofing (Scotland) Ltd, • Please detail any measures taken in response to our client’s accident.
Date of Response: 07/10/2026
View Response: 11917.pdf
Freedom of Information Request Reference: 11916
Date Received: 15/09/2026
Summary:
1. How many of the following intra-vitreal injections/implants has your trust administered in the four-month period from May to August 2026: • Aflibercept – Eylea only (Any strength: 2mg or 8mg) • Aflibercept – Eylea 8mg only (21mg/184microlitres solution or 30.1mg/263microlitres solution) • Aflibercept - Biosimilar (any brand other than Eylea) • Bevacizumab • Dexamethasone • Faricimab • Fluocinolone acetonide • Ranibizumab - including all Biosimilars
Date of Response: 07/10/2026
View Response: 11916.pdf
Freedom of Information Request Reference: 11915
Date Received: 15/09/2026
Summary:
Please provide the following information for Priority 2 (P2) surgery for each month from May 2022 to September 2022 inclusive: 1. The number of patients waiting for P2 surgery at the end of each month. 2. The number of patients who underwent P2 surgery during each month. 3. The waiting time for P2 surgery, preferably broken down into: o the median waiting time; o the mean waiting time, if available; and o the number and/or percentage of patients waiting more than 4 weeks, 8 weeks and 12 weeks. 4. The longest waiting time recorded for a patient awaiting P2 surgery in each month. 5. If available, please provide the above information broken down by surgical specialty.
Date of Response: 07/10/2026
View Response: 11915.pdf
Freedom of Information Request Reference: 11912
Date Received: 11/09/2026
Summary:
I have a freedom of information request related to the diagnosis and treatment of Spinal Muscular Atrophy. Your answers to the following questions would be greatly appreciated. Question 1. Within your trust, how many patients currently have a diagnosis for: SMA Type 1, aged less than 6 months (ICD-10 Code G12.0) SMA Type 2, aged 6–17 months (ICD-10 Code G12.1) SMA Type 3, aged 18 months–17 years (ICD-10 Code G12.1) SMA Type 4, aged 18 years and over (ICD-10 Code G12.1) SMA Unspecified (ICD-10 Code G12.9) Question 2. Please provide the number of total patients and new patients* who have been treated in the last 4 months (May to August 2026) with the following products: Drug Type Total Patients New Patients* Evrysdi (Risdiplam) Total Tablets Oral Solution Spinraza (Nusinersen) Total 12 mg/5 mL Intrathecal Injection 28 mg/5 mL Intrathecal Injection Zolgensma (Onasemnogene) Total *New patients are defined as patients who were not treated with any of Spinraza (Nusinersen), Evrysdi (Risdiplam), or Zolgensma (Onasemnogene abeparvovec) in the previous 4-month period (January to April 2026). Patients who switch between formulations, strengths, or routes of administration of these therapies are not considered new patients. Question 3. Of the total patients treated in the last 4 months (May to August 2026) with Evrysdi (Risdiplam), please provide the number of patients that were treated with Spinraza (Nusinersen) in the previous 4 months (January to April 2026). Question 4. Of the total patients treated in the last 4 months (May to August 2026) with Zolgensma (Onasemnogene), please provide the number of patients that were treated with Spinraza (Nusinersen) in the previous 4 months (January to April 2026). Question 5. Of the total patients treated in the last 4 months (May to August 2026) with Spinraza (Nusinersen), please provide the number of patients that were treated with Evrysdi (Risdiplam) in the previous 4 months (January to April 2026).
Date of Response: 07/10/2026
View Response: 11912.pdf
Freedom of Information Request Reference: 11911
Date Received: 09/09/2026
Summary:
please provide the following information about the Trust's purchasing of peripheral intravenous cannulas. For each of the financial years 2023/24, 2024/25 and 2025/26, please provide: 1. the manufacturer and brand of each product purchased; 2. the catalogue or product code (NPC, or the Trust's own code); 3. the quantity purchased (please state the unit - e.g. each, box, case); 4. the total expenditure, excluding VAT; 5. the name of the supplier the Trust purchased from, where this differs from the manufacturer (for example NHS Supply Chain or another distributor); 6. the contract or framework under which the purchase was made, and its start and end dates; 7. where the Trust changed supplier or manufacturer during this period, the previous supplier or manufacturer and the date of change.
Date of Response: 02/10/2026
View Response: 11911.pdf
Freedom of Information Request Reference: 11906
Date Received: 09/09/2026
Summary:
The aim is to understand how NHS Trusts currently deliver Vascular Access Devices Insertion services, including service structure, leadership, staffing and insertion practices. I would be grateful if you could provide the information requested below: 1. Does your Trust provide: o PICC insertion (Yes/No) o Midline insertion (Yes/No) o Totally Implantable Venous Access Device Chest/Arm insertion (Yes/No) o Tunnelled Central Vascular Access Devices insertion (Yes/No) 2. Who provides these procedures? o Dedicated Vascular Access Team o Interventional Radiology o Anaesthetics o OPAT Service o Nutrition service o Medical Teams o Nursing Teams o Other (please specify) 3. Who performs PICC/Midline insertions? o Nurses o Doctors o Radiographers o Other 4. Who performs TIVAD/Tunnelled VAD insertions? o Nurses o Doctors o Radiographers o Other 5. Where are PICCs/Midlines inserted? Please select all that apply: o Procedure room o Patient bedside o Interventional Radiology o Theatre o Other (please specify) 6. Where are TIVAD/Tunnelled VAD inserted? Please select all that apply: o Procedure room o Patient bedside o Interventional Radiology o Theatre o Other (please specify) 7. Does your Trust have a dedicated Vascular Access Team? (Yes/No) 8. If yes, please provide: o Team composition (e.g. nurses, doctors, advanced practitioners) o Number of staff (WTE if available) o Whether the service is nurse-led, doctor-led, or jointly led 9. Under which department/directorate does the service sit? 10. If readily available, please provide the number of PICCs, Midlines, TIVAD/Tunnelled VAD inserted during the most recent complete financial year.
Date of Response: 07/10/2026
View Response: 11906.pdf
Freedom of Information Request Reference: 11905
Date Received: 10/09/2026
Summary:
Any correspondence between the NHS Lothian chief executive and government ministers about the planned proposals to reduce the number of health boards, dating back to 2024?
Date of Response: 07/10/2026
View Response: 11905.pdf
Freedom of Information Request Reference: 11904
Date Received: 09/09/2026
Summary:
Q1. How many patients were treated by the rheumatology department in the past 3 months with the following: •Tocilizumab – for any disease •Tocilizumab for rheumatoid arthritis (RA) only •Tocilizumab for giant cell arteritis (GCA) only Q2. How many patients were treated by the ophthalmology department (for any disease) in the past 3 months with Tocilizumab? Q3. How many patients were treated in A&E in the past 3 months for giant cell arteritis (GCA) with Tocilizumab? Q4. In the past 3 months, how many patients with a primary diagnosis of GCA (ICD10 codes M31.5 or M31.6) were: •Admitted as an inpatient •Treated in A&E
Date of Response: 01/10/2026
View Response: 11904.pdf
Freedom of Information Request Reference: 11902
Date Received: 08/09/2026
Summary:
I wish to make a Freedom of Information Request for all consultation papers regarding the potential merger of NHS Lothian into other health boards.
Date of Response: 07/10/2026
View Response: 11902.pdf
Freedom of Information Request Reference: 11901
Date Received: 08/09/2026
Summary:
The most up to date timeline for the delivery of a new Princess Alexandra Eye Pavilion, including any delays.
Date of Response: 01/10/2026
View Response: 11901.pdf
Freedom of Information Request Reference: 11900
Date Received: 08/09/2026
Summary:
Please provide all financial expenditure, central funding allocations, specific grants, and research funding allocated by your organization for the following clinical and service areas: 1. Endometriosis (including specialized gynaecological care and diagnostic pathways) 2. Miscarriages/Pregnancy Loss (including early pregnancy assessment units and post-loss support services) 3. Contractual Sexual Health Services (including commissioned STI testing, contraception services, and community sexual health clinics) For each of the three areas above, please provide the total financial figures broken down by the following financial years: - Financial Year 2016/17 - Financial Year 2017/18 - Financial Year 2018/19 - Financial Year 2019/2020 - Financial Year 2020/21 - Financial Year 2021/22 - Financial Year 2022/23 - Financial Year 2023/24 - Financial Year 2024/25 - Financial Year 2025/26 Specification of Data requested: - If exact figures for 2025/26 are not yet finalized or audited, please provide the most up-to-date budgeted allocations or projected spend figures.
Date of Response: 07/10/2026
View Response: 11900.pdf
Freedom of Information Request Reference: 11897
Date Received: 08/09/2026
Summary:
I would be grateful if you could provide the following information for each of the financial years: • 2023/24 • 2024/25 •2026 Please provide the information separately for: 1. Atrial Septal Defect (ASD) closure 2. Patent Foramen Ovale (PFO) closure 3. Left Atrial Appendage Occlusion/Closure (LAAO/LAAC) For each procedure category and financial year, please provide: A. PROCEDURE VOLUMES 1. The total number of ASD closure procedures performed. 2. The total number of PFO closure procedures performed. 3. The total number of LAAO/LAAC procedures performed. B. DEVICE PRICING AND EXPENDITURE For each manufacturer/product identified above, please provide: 1. The actual unit price paid by the Trust, excluding VAT. 2. Supplier/distributor name, where recorded. 3. Procurement route used (NHSSC or other) If the Trust is unable to disclose the exact unit price, please instead provide: • total number of devices purchased, and • total expenditure on that device, so that an average unit cost can be calculated.
Date of Response: 07/10/2026
View Response: 11897.pdf
Freedom of Information Request Reference: 11895
Date Received: 07/09/2026
Summary:
Q1 Please provide me with your evaluation of your ICB's winter plan for 2025-2026 Q2 Please provide the winter plan for 2026-2027.
Date of Response: 07/10/2026
View Response: 11895.pdf
Freedom of Information Request Reference: 11894
Date Received: 07/09/2026
Summary:
Question 1: What are the referral criteria for dementia (memory) assessment within NHS Lothian (i.e., as provided by Older People's Mental Health teams/Memory Assessment and Treatment Service/Older Adult Mental Health team or equivalent)? In other words, on what basis are decisions made whether to accept or reject such referrals? If the criteria vary depending on team/locality, please provide a breakdown. Questions 2: The following prisons fall within the NHS Lothian footprint: HMP Edinburgh (EH11 3LN) and HMP Addiewell (EH55 8QF) For each of the above prisons, does the corresponding dementia (memory) assessment service (i.e., the service covering the geographic area within which the prison is situated) accept referrals from the prison healthcare team of prisoners for the purposes of dementia (memory) assessment, provided all other referral criteria are met? If the answer varies by team, please provide a breakdown. If for any team the answer is no, what is the reason for not accepting such referrals? Question 3: Do NHS Lothian dementia (memory) assessment services accept referrals from prisons outwith the NHS Lothian footprint for prisoners who resided within the NHS Lothian footprint at the time of their incarceration, for the purposes of dementia (memory) assessment? If the answer varies by team, please provide a breakdown.
Date of Response: 01/10/2026
View Response: 11894.pdf
Freedom of Information Request Reference: 11892
Date Received: 07/09/2026
Summary:
For each of 2021/22, 2022/23, 2023/24, 2024/25 and 2025/26 (to date): 1. Number of complaints received that you code to mental health services, CAMHS, and psychological therapies (three rows, or your actual specialty codes — please list the codes). 2. Of those closed in each year: number upheld, partially upheld, and not upheld, by the same service split, and by Stage 1 / Stage 2 if held. 3. Number of SPSO decisions in those years that you record as relating to those services, and how many were upheld or partially upheld, if you hold that.
Date of Response: 08/10/2026
View Response: 11892.pdf
Freedom of Information Request Reference: 11889
Date Received: 07/09/2026
Summary:
Please treat Psychological Therapies (PT) and CAMHS as two separate services. Do not combine them. Please exclude neurodevelopmental / ADHD-only pathways unless you label those rows separately. For each of PT and CAMHS, and for each of financial years 2021/22, 2022/23, 2023/24, 2024/25 and 2025/26 (or calendar years if that is how the extract is held): 1. Of people who started treatment in that year: a. the 95th percentile waiting time in days (say whether adjusted or unadjusted); b. the 99th percentile waiting time in days; c. the number who started after waiting 365 days or more; d. the number who started after waiting 730 days or more. Please do not provide a single maximum if you consider section 38 applies to that one number. I still want (a)–(d). If you only hold completed waits in week bands beyond 104 weeks, give the count in the >104-week band. 2. Of people still waiting to start treatment at the latest extract date you hold: a. the extract date and whether waits are adjusted or unadjusted; b. total still waiting; c. 95th and 99th percentile current wait in days; d. number waiting 365 days or more; e. number waiting 730 days or more. Again, do not provide a single identifiable maximum if section 38 applies. Counts and percentiles are sufficient.
Date of Response: 07/10/2026
View Response: 11889.pdf
Freedom of Information Request Reference: 11882
Date Received: 04/09/2026
Summary:
I am writing to request information under the Freedom of Information (Scotland) Act 2002 relating to the development and selection of locations for GP-led walk-in services within NHS Lothian. Please provide: 1. Any criteria, scoring framework, assessment methodology or other guidance used by NHS Lothian when identifying, assessing or recommending locations for GP-led walk-in services. 2. Any assessments, option appraisals, briefing papers, reports or submissions produced since 1 October 2025 which considered Midlothian as a potential location for a GP-led walk-in service. 3. Details of any locations within Midlothian which have been considered for such a service, including the outcome or current status of that consideration. 4. The registered patient population of each GP practice within the Midlothian Health and Social Care Partnership area for each year from 2021 to 2026, where held. 5. The whole-time-equivalent GP workforce associated with each Midlothian GP practice for each year from 2021 to 2026, where held. 6. The number of contacts with NHS Lothian GP Out of Hours services involving patients resident within Midlothian for each of the financial years 2021/22 to 2025/26, where this information can be provided without identifying individual patients. 7. Any analysis undertaken by NHS Lothian of current or future primary-care capacity requirements arising from population growth, demographic change or housing development within Midlothian.
Date of Response: 07/10/2026
View Response: 11882.pdf
Freedom of Information Request Reference: 11876
Date Received: 02/09/2026
Summary:
I would like to request anonymised statistical information regarding patients who have required unplanned NHS Lothian assessment, treatment and/or admission following complications arising after privately funded cosmetic or plastic surgery. For each of the calendar years 2024, 2025 and 2026 to date, please provide: 1. The total number of patients who required unplanned assessment and/or treatment from NHS Lothian following privately funded cosmetic or plastic surgery. I would be grateful if this is not limited solely to Emergency Department attendances. Where recorded, please include patients who: • attended an Emergency Department; • were transferred or referred from a private hospital/provider; • were referred directly to, admitted under, or assessed by Plastic Surgery, General Surgery or another relevant surgical/specialist team; • were reviewed by an NHS surgeon or plastic surgeon in relation to a postoperative complication; • attended a surgical assessment unit, ward or other NHS service; • or otherwise required unplanned NHS assessment or treatment relating to a complication following privately funded cosmetic or plastic surgery. 2. Of these patients, the number who required admission to an NHS Lothian hospital. 3. Where recorded, please provide a breakdown of the number of patients who required: • emergency or unplanned surgery/re-operation; • treatment for postoperative haemorrhage or haematoma; • treatment for postoperative infection; • treatment for wound complications; • blood transfusion; • inpatient admission or observation following the complication. 4. Where available, please provide a breakdown by the NHS hospital or service which provided the assessment or treatment, including St John’s Hospital, Livingston. 5. Where the treating specialty is recorded, please provide a breakdown by specialty, particularly Plastic Surgery and General Surgery. 6. Where the type of original private procedure is recorded, please provide a breakdown by procedure or category of procedure. In particular, I would be grateful for any figures held relating to complications following breast surgery, including: • breast reduction; • breast augmentation; • mastopexy/breast uplift; • or other cosmetic breast procedures. 7. For the cases included within the figures above, where the originating private hospital/provider is recorded and can be disclosed without identifying an individual patient, please provide the name of the private hospital/provider associated with each case or reported category. For example, where a case involved postoperative haemorrhage/haematoma, infection, wound complication, hospital admission or emergency re-operation, I would be grateful if the originating private provider could also be shown alongside that information where held and where disclosure is permitted. I am not requesting any information capable of identifying the individual patient. I am seeking only the name of the private healthcare provider at which the original privately funded procedure was undertaken. If providing provider information at individual case level would create a risk of patient identification due to small numbers, please instead provide the information grouped by private provider, showing for each provider, where held: • number of patients requiring NHS assessment or treatment; • nature/category of complication; • number requiring NHS admission; • number requiring emergency or unplanned surgery/re-operation; • type/category of original private procedure; • NHS hospital/service providing treatment; • and treating specialty. Within this information, please specifically include St Ellen’s Hospital, Livingston and/or Cosmedicare where they are recorded as the originating private provider. 8. If NHS Lothian cannot provide a complete provider breakdown, please confirm whether St Ellen’s Hospital and/or Cosmedicare can nevertheless be identified within the information held and, if so, please provide the relevant aggregate figures for 2024, 2025 and 2026 to date. 9. Please confirm whether NHS Lothian routinely records the originating private hospital/provider when a patient requires NHS assessment or treatment for a complication following privately funded surgery. If so, please confirm how this information is recorded or coded. If the originating provider is not held as a discrete or routinely reportable field, please confirm whether it may instead be identifiable through routinely recorded information such as: • referral source; • transfer source; • treating specialty; • provider information; • onward referral; • discharge destination; • or follow-up arrangements. 10. Where recorded, please provide the number of patients who, following NHS Lothian assessment, treatment and/or admission for a complication of privately funded cosmetic or plastic surgery, were discharged or referred back to their original private hospital/provider for ongoing postoperative care or follow-up. Where the destination provider can be identified, I would specifically request that the private provider is named alongside the aggregate information where disclosure is possible, including St Ellen’s Hospital and/or Cosmedicare where applicable. If a numerical figure cannot be provided, please confirm whether onward referral, discharge or return to a named private provider is held as a searchable or reportable field. 11. Where NHS Lothian holds information regarding the financial cost of providing unplanned or emergency NHS treatment for complications arising following privately funded cosmetic or plastic surgery, please provide any available aggregate figures for 2024, 2025 and 2026 to date.
Date of Response: 08/10/2026
View Response: 11876.pdf
Freedom of Information Request Reference: 11850
Date Received: 20/08/2026
Summary:
1. How many significant/serious adverse events there has been within maternity and neonatal services between 1st Jan 2019 and 30th June 2026 (If 2026 data not available, until 31st December 2025) - can this be broken down by year and maternity vs neonatal services 2. Can this data then indicate whether it resulted in death, major injury or minor injury, again distinguishing between maternity and neonatal services and by year 3. Can the data from Q1+2 be further broken down by hospital where they occurred 4. From these cases, how many had a significant adverse event review (SAER) commissioned and how many days from the event did they take to complete
Date of Response: 07/10/2026
View Response: 11850.pdf
Freedom of Information Request Reference: 11838
Date Received: 18/08/2026
Summary:
I therefore request an internal review of this response. In particular, I would ask the reviewer to consider whether the information can be provided in a more proportionate form, for example: • The total number of days the NICU was closed to admissions due to capacity in each year from 2021–2026. • If the exact number cannot be provided without reviewing every individual daily sheet, please provide whatever annual or monthly totals are already available. • If those totals genuinely do not exist, please explain why this information is not routinely collated. • Please also clarify whether there is a central system, electronic record, capacity report, escalation log or other mechanism from which NICU closures can be identified without manually reviewing every daily capacity sheet. • If providing six years of data exceeds the cost limit, please consider narrowing the request to 2025 and 2026 rather than refusing the request in its entirety.
Date of Response: 05/10/2026
View Response: 11838.pdf
Freedom of Information Request Reference: 11787
Date Received: 30/07/2026
Summary:
- Any workforce modelling undertaken since 2023 regarding the oncology, radiology, pathology and cancer nursing workforce required to achieve national cancer waiting time Standards. - Please provide the current policy, protocol or guidance governing the prioritisation or escalation of patients with suspected aggressive or rapidly progressing cancers. - Any audits, reviews or analyses undertaken since 2023 regarding patients whose cancer diagnosis or treatment occurred later than clinically recommended. - Any Serious Adverse Event Reviews, Significant Adverse Event Reviews or equivalent investigations since 2023 where delay in cancer diagnosis or treatment was identified as a contributory factor.
Date of Response: 07/10/2026
View Response: 11787.pdf
Freedom of Information Request Reference: 11756
Date Received: 23/07/2026
Summary:
Please provide the following details regarding your organisation’s lone worker protection arrangements: 1. What lone worker device(s), system(s), or service(s) your Trust currently uses (e.g., dedicated lone worker alarms, smartphone apps, GPS tracking devices, SOS fobs, monitoring platforms, etc.). • Please include the supplier’s name, product name, and type of solution (e.g., hardware device, mobile app, integrated security system). 2. Is the system (if used) monitored by an Alarm Receiving Centre (ARC) or any other system to respond to alarm activations? 3. The number of staff currently registered to use these lone worker devices or systems. 4. How do you monitor percentage of use by your staff? 5. The annual cost of the lone worker system(s) or service(s), including any licensing, subscription, or maintenance fees. 6. Contract details, including: • Contract start date • Contract end date • Whether there are extension options • The procurement route used (e.g., direct award, framework, tender) 7. If applicable, please confirm whether the Trust is considering changing or introducing a lone worker system(s) in the next 12–24 months?
Date of Response: 01/10/2026
View Response: 11756.pdf
Freedom of Information Request Reference: 11726
Date Received: 16/07/2026
Summary:
The total number of staff who have received exit payments, settlement agreements, or redundancy/severance packages in each of the last five financial years (2021-22 to 2025-26). For each payment, please provide: a) The financial year in which the payment was made b) The reason for departure (e.g. compulsory redundancy, settlement agreement, etc) c) The cost of the payment
Date of Response: 07/10/2026
View Response: 11726.pdf
Freedom of Information Request Reference: 11709
Date Received: 13/07/2026
Summary:
1. Aseptic labs and services (pharmacy cleanrooms) 1a. How many aseptic preparation units (pharmacy cleanrooms where sterile medicines are made up) does the trust operate, and what does each mainly prepare (for example chemotherapy, intravenous additives, intravenous feeding, or radiopharmacy, which is radioactive tracers for scans? 1b. For each aseptic unit, in what year was it built or last fully refurbished? A full refurbishment includes replacing the cleanroom air-handling or ventilation. 1c. Does each unit hold a manufacturing “specials” licence from the medicines regulator (the MHRA), or does it operate under the pharmacy exemption (section 10 of the Medicines Act) without a licence? 1d. Has the trust assessed its aseptic units against the current sterile-preparation standard (the updated Annex 1 rules on cleanroom air quality)? If so, do any units fall short of it or need upgrading to comply? 1e. Is any aseptic preparation outsourced to a commercial or external NHS unit? If so, to which provider, and roughly what share of the workload? 1f. Are there approved or planned schemes in the next five years to build, expand, replace or refurbish aseptic units? For each, please give a brief description, an indicative value, and the expected date. 1g. In the last five years, has limited aseptic capacity affected the trust's ability to prepare chemotherapy or other sterile medicines, or led to buying them in from an outside provider? Please describe briefly. 2. Surgical robots and theatre technology 2a. How many surgical robotic systems does the trust currently operate, and of what make and model? 2b. Are there approved or planned schemes to acquire further robotic systems within the next five years? Please give the number and the expected date. 2c. Have any operating theatres been enlarged or upgraded to take robotic or hybrid use in the last five years, or are any such works planned? If so, please describe briefly. 3. Wards and day surgery 3a.. What was the day-case rate for elective surgery (the percentage of elective procedures carried out as day cases) over the most recent twelve months? 3b. Are there approved or planned schemes within the next five years to refurbish or replace surgical wards, or to create a new day-surgery unit? Please describe briefly, with expected dates. 4. Estate agency and continuity 4a. Is RAAC present anywhere in the trust's estate? If yes, is any of it in, or directly adjacent to, operating theatres, endoscopy or decontamination facilities? 4b. In the last five financial years, has the trust used any temporary, mobile or modular clinical facility (theatre, ward, endoscopy, decontamination or diagnostic unit)? For each, please give the facility type, the supplier where recorded, the duration of use, and the total spend. 4c. Does the trust hold a current decant or continuity plan that anticipates moving surgical, endoscopy or decontamination services out of their normal location to allow refurbishment or replacement within the next five years? 5. Capital programme and procurement 5a. Please list the trust's currently approved or planned capital schemes for the next five years that affect operating theatres, endoscopy, decontamination, aseptic services, or surgical wards. For each, please give the scheme name, a brief description, an indicative value, and the expected start and finish dates. 5b. Through which framework or frameworks does the trust usually procure temporary or modular clinical buildings (for example, NHS Supply Chain or Crown Commercial Service)? 5c. In the last five years, has the trust considered or used private finance, third-party investment, or a rental or managed-service arrangement to provide clinical capacity? If so, please describe briefly.
Date of Response: 01/10/2026
View Response: 11709.pdf
Freedom of Information Request Reference: 11684
Date Received: 07/07/2026
Summary:
Where a question asks about future plans, please provide only information the trust currently holds in recorded form, such as an approved business case or an entry in the capital programme. Where no time period is given, the most recent available figure is fine.
Date of Response: 01/10/2026
View Response: 11684.pdf
Freedom of Information Request Reference: 11639
Date Received: 30/06/2026
Summary:
For each calendar year from 2019 to 2026 (most recent): The total number of incidents where a patient fall was reported, broken down by hospital.
Date of Response: 07/10/2026
View Response: 11639.pdf
Freedom of Information Request Reference: 11910
Date Received: 11/09/2026
Summary:
We would be obliged if you could please provide us with information in relation to the waiting times for referrals for spinal cord stimulation under the categories both routine and urgent as at September 2026. By this we mean, if a patient were referred for spinal cord stimulation in September 2026, what would be the average wait time for this patient to receive treatment under these categories.
Date of Response: 30/09/2026
View Response: 11910.pdf
Freedom of Information Request Reference: 11891
Date Received: 07/09/2026
Summary:
For each of financial years 2021/22, 2022/23, 2023/24, 2024/25 and 2025/26 (to date, with the cut-off date stated): 1. How many people whose care you funded were in an inpatient mental health, learning disability or forensic placement outside this Board's own hospitals at year end (or the nearest census you hold), split: a. outwith NHS Scotland; b. in Scotland but not in this Board (another NHS Board or independent provider in Scotland). If (a) is only held as the national census figure, say so and answer (b). 2. Total expenditure (£) on those placements in each year, split (a)/(b) if held. If only a single total is held, provide that and say so.
Date of Response: 29/09/2026
View Response: 11891.pdf
Freedom of Information Request Reference: 11890
Date Received: 07/09/2026
Summary:
As at the most recent date for which figures are held (please state the date), please provide Whole Time Equivalent for: 1. Consultant psychiatrists 2. Other career-grade / SAS psychiatrists, if recorded 3. Psychology services clinical staff (as you report to NES), with applied psychologists separately if held 4. Registered mental health nurses For each of 1–4 please provide: a. funded establishment WTE b. staff in post WTE c. vacancy WTE d. locum or agency WTE covering vacancies, if recorded If you hold a split by adult mental health, CAMHS, and older-age psychiatry/nursing, please provide that split. If not held, board totals are sufficient.
Date of Response: 28/09/2026
View Response: 11890.pdf
Freedom of Information Request Reference: 11885
Date Received: 04/09/2026
Summary:
Does the NHS Lothian Job Evaluation Team consider a "master's level qualification" to be at the same academic level as a "masters degree level qualification" for the purposes of evaluating the Knowledge Training and Experience factor of a nursing job? And if not, why not? And how many NHS Lothian job evaluations, since 2018, will have been affected by any misunderstanding of the meaning of the word "level"? This seems to have been an issue with the NHS Lothian Specialist School Nurse job evaluation in both 2018 and 2025. Please fully explain.
Date of Response: 28/09/2026
View Response: 11885.pdf
Freedom of Information Request Reference: 11879
Date Received: 03/09/2026
Summary:
On how many occasions were children hospitalised for (a) alcohol-related, or (b) drug-related injuries or illnesses in (i) 2016-17, (ii) 2017-18 and (iii) 2018-19, broken down by (A) 0-4 years olds, (B) 5-9 year olds, (C) 10-13 year olds, (D) 14-17 year olds. If an incident was related to both drugs and alcohol, and is therefore included in both categories, please provide details of on how many occasions this occurred, broken down by year and age category. Please include: • both attendances at an emergency department and admissions to hospital • those admitted for observation • cases of accidental consumption
Date of Response: 28/09/2026
View Response: 11879.pdf
Freedom of Information Request Reference: 11870
Date Received: 21/08/2026
Summary:
I would be grateful if you could provide us with a broad indication of the current position, particularly in relation to children in the East Lothian/Lothian area. It would be helpful to understand: * The current approximate waiting time for children awaiting a neurodevelopmental assessment; * Whether waiting times differ between autism, ADHD and wider neurodevelopmental assessments; * Approximately how many children are currently waiting, if this information is available; * Whether there is currently a significant backlog within the service; * Whether families are given any indication of their likely assessment timescale once they are placed on the waiting list; and * What support is available to children and families while they are waiting. We appreciate that individual waiting times will vary depending on the child and the pathway involved. We are therefore not seeking information about any individual patient, but rather a general picture of the current position so that we can give parents accurate information. It would also be helpful if you could clarify whether children waiting specifically for a neurodevelopmental assessment are included within the published CAMHS waiting-time figures, or whether these assessments are recorded separately.
Date of Response: 28/09/2026
View Response: 11870.pdf
Freedom of Information Request Reference: 11863
Date Received: 28/08/2026
Summary:
The difficulty with the response is that my request contained 13 separate numbered points covering several different categories of recorded information. NHS Lothian has largely provided one general answer relating to the difficulty of extracting complication information from individual patient records, followed by reliance on section 12(1) and a section 17 notice. That does not appear to answer the request as made. I accept that questions 2 and 3 may require consideration of clinical records if NHS Lothian has no centrally extractable complication dataset. However, that issue does not explain the absence of answers to separate requests for correspondence, reports, meeting records, policy material, government requests for evidence, advisory-group participation and stakeholder correspondence. In particular, I cannot identify a substantive response to questions 1 and 5 to 13. Question 1 requested correspondence, briefings, reports, presentations, meeting records or advice exchanged with the Scottish Government, Healthcare Improvement Scotland, Public Health Scotland or another body concerning regulation, practitioner restrictions, HIS-registered premises, prescriber or healthcare-professional requirements and procedure classification. Questions 5 to 13 concerned, amongst other things, comparative analyses, information supplied to government, requests received for evidence, advice submitted by NHS Lothian, participation of Board staff in relevant government groups or meetings, assessments of the effect of the legislation upon NHS services, records concerning independent practitioner participation, records concerning the role or standing of named stakeholder organisations, and correspondence with those organisations. None of those categories would ordinarily require NHS Lothian to examine individual patient files. I therefore ask the reviewer to establish what searches were actually undertaken for each of questions 1 and 5 to 13, which departments, offices or record systems were searched, and whether relevant corporate, executive, governance, public health, clinical management, communications and policy records were considered. If NHS Lothian's position is that no recorded information is held for any particular numbered question, please provide a separate section 17 notice for that question so that it is clear what information the Board says it does and does not hold. I would also ask the reviewer to reconsider the application of section 12(1). The response says there would be "significant cost implications", but does not provide an estimated cost, explain how the estimate was calculated, state the number of records which would require examination, or explain which particular numbered parts of my request exceed the statutory cost limit. Please therefore provide the calculation relied upon when applying section 12(1), including the search activities, estimated staff time and costs attributed to them. There is also an apparent inconsistency between relying upon section 12(1), which appears to proceed on the basis that relevant information may exist but would be too costly to retrieve, and then issuing a section 17 notice stating that NHS Lothian does not hold "the requested information". Those are materially different positions. I would be grateful if the review could distinguish clearly between: 1. information which NHS Lothian holds but considers too costly to locate or extract under section 12(1); 2. information which NHS Lothian does not hold for the purposes of section 17; and 3. information which can be provided without exceeding the cost limit. I would also ask the reviewer to consider whether NHS Lothian complied with its duty to provide reasonable advice and assistance. If obtaining the full figures requested in questions 2 and 3 would exceed the cost limit, please identify whether any existing extracts, audits, incident reports, departmental statistics, reports, summaries or narrower recorded information can be provided without requiring a manual review of every patient record. Finally, the response from Plastic Surgery states that the department does not keep a note of complications from patients who had procedures carried out by a "non-medical practitioner". My request used a specific definition of "independent aesthetic practitioner". Please confirm whether searches were conducted using the definition in my request rather than relying upon a different or narrower category. I am not asking NHS Lothian to create new information. I am asking it to reconsider whether existing recorded information falling within each separate part of the request has been properly searched for and whether the exemptions and information-not-held notice have been applied to the appropriate parts of the request. Please conduct a fresh review and provide a point-by-point outcome for questions 1 to 13.
Date of Response: 29/09/2026
View Response: 11863.pdf
Freedom of Information Request Reference: 11859
Date Received: 28/08/2026
Summary:
1. The answer to my previous question 1 refers to pausing new referrals "until there was surgical throughput and capacity”. Does that mean that that throughput and capacity still doesn’t exist? 2. What additional resources, human and otherwise, are needed to create sufficient surgical throughput and capacity (assuming that “no” is the answer to my first question)? 3. Are you saying that the number of consultants makes no difference to the treatment that can be offered, and will not affect the decision to reopen the pathway? 4. How many other WTE doctors are there? 5. How big is the “available budget”? 6. When was the available budget last decided? 7. Who made that decision? 8. How much bigger would the available budget have to be before the pathway could be reopened?
Date of Response: 28/09/2026
View Response: 11859.pdf
Freedom of Information Request Reference: 11855
Date Received: 24/08/2026
Summary:
Q1. Does your health board currently provide transport for patients to and from in-centre dialysis? If yes: a. Please list each mode of transport you provide. b. Please list which modes of transport in 1a are needs assessed. (Definition of needs assessed = a patient’s medical, physical, and social circumstances are assessed to determine their eligibility for transport to and from in-centre dialysis) c. Please provide a link to, or outline of, the needs assessment criteria and policy for each mode of transport identified in 1b. d. Please list which modes of transport in 1a are means tested? (Definition of means tested = a patient qualifies for transport to and from in-centre dialysis due to financial hardship or low income and may be in receipt of government benefits) e. Please provide a link to, or outline of, the means tested criteria and policy for each mode of transport identified in 1d. f. Are any of the modes of transport listed in 1a restricted to certain days and/or to certain times of day that a patient can use them travel to and from in-centre dialysis? Travel by public transport Q2. Does your health board currently reimburse kidney patients who travel by public transport to and from in-centre dialysis? If YES: a. Are patients reimbursed in full for their travel by public transport? If NO: Please outline the rates utilised to reimburse patients who use public transport. b. Are all patients who travel by public transport to and from in-centre dialysis reimbursed for their travel, or is this means tested? (Definition of means tested = a patient qualifies for transport to and from in-centre dialysis due to financial hardship or low income and may be in receipt of government benefits) If means tested: Please provide a link to, or outline of, the means tested criteria and policy for travel by public transport to and from in-centre dialysis. Travel by private taxi Q3. Does your health board currently reimburse kidney patients who travel by private taxi to and from in-centre dialysis? (Definition of private taxi = a taxi organised by the patient and not agreed and arranged by the hospital/ dialysis unit) If YES: a. Are patients reimbursed in full for their travel by private taxi? If NO: Please outline the rates utilised to reimburse patients who use private taxis. b. Are all patients who travel by private taxi to and from in-centre dialysis reimbursed for their travel, or is this means tested? (Definition of means tested = a patient qualifies for transport to and from in-centre dialysis due to financial hardship or low income and may be in receipt of government benefits) If means tested: Please provide a link to, or outline of, the means tested criteria and policy for travel by private taxi and from in-centre dialysis. Travel by private car Q4. Does your health board currently reimburse the cost of fuel for kidney patients who travel by private car to and from in-centre dialysis? (Definition of private car = travel in their own vehicle, or a family member’s or friend’s car to and from incentre dialysis) If YES: a. Are patients reimbursed in full for their fuel costs when they travel by private car to and from in-centre dialysis? If NO: Please outline the rates at which their fuel costs are reimbursed. b. Are all patients who travel by private car to and from in-centre dialysis reimbursed for their fuel costs, or is this means tested? (Definition of means tested = a patient qualifies for transport to and from in-centre dialysis due to financial hardship or low income and may be in receipt of government benefits) If means tested: Please provide a link to, or outline of, the means tested criteria and policy for travel by private car to and from in-centre dialysis. Other comments Q5. Do you have any other comments about the dialysis transport services your health board provides? - for e.g. whether there is a review of renal transport services planned soon in your health board or of this is ongoing, or if you have specific issues and concerns about the service.
Date of Response: 29/09/2026
View Response: 11855.pdf
Freedom of Information Request Reference: 11832
Date Received: 17/08/2026
Summary:
I'd like to know the bed availability at the Royal Edinburgh hospital for mental health and St John's hospital in Livingston during 21st October 2024 until 21st November 2024.
Date of Response: 28/09/2026
View Response: 11832.pdf
Freedom of Information Request Reference: 11733
Date Received: 17/07/2026
Summary:
1. In the last 6 months (November 2025 to April 2026), how many adult patients were treated by the dermatology department, excluding patients referred for cancer/suspected cancer? 2. Do you run a specific clinic for patients with atopic dermatitis? 3. In the last 6 months (November 2025 to April 2026), how many adult patients with atopic dermatitis were treated by the dermatology department? 4. In the last 6 months (November 2025 to April 2026), how many adult patients with atopic dermatitis were treated with the following products: a. Immunosuppressants (Azathioprine, Ciclosporin, Methotrexate, Mycophenolate mofetil, Pimecrolimus, or Tacrolimus) b. Abrocitinib c. Baricitinib d. Dupilumab e. Lebrikizumab f. Tralokinumab g. Upadacitinib h. Nemolizumab i. Delgocitinib 5. In the last 6 months (November 2025 to April 2026), how many adult patients with atopic dermatitis were started on the following products: a. Immunosuppressants (Azathioprine, Ciclosporin, Methotrexate, Mycophenolate mofetil, Pimecrolimus, or Tacrolimus) b. Abrocitinib c. Baricitinib d. Dupilumab e. Lebrikizumab f. Tralokinumab g. Upadacitinib h. Nemolizumab i. Delgocitinib
Date of Response: 30/09/2026
View Response: 11733.pdf
Freedom of Information Request Reference: 11661
Date Received: 02/07/2026
Summary:
1. A complete list of CAMHS vacancies currently open in NHS Lothian. Please provide for each vacancy the name of the position and how many days the vacancy has been open for. Please note that websites do not provide all of that info, so I would appreciate the board providing it. 2. The total number of CAMHS positions in NHS Lothian 3. The total number of those CAMHS positions that are currently filled/occupied. Please provide the number (please also provide it as a percentage), that are currently occupied and the number (please also provide it as a percentage) that aren’t occupied.
Date of Response: 28/09/2026
View Response: 11661.pdf
Freedom of Information Request Reference: 11964
Date Received: 24/09/2026
Summary:
Request in relation to personal information.
Date of Response: 24/09/2026
View Response: 11964.pdf
Freedom of Information Request Reference: 11954
Date Received: 22/09/2026
Summary:
Long term care is provided to clients on an ongoing basis and varies from high intensity provision such as nursing care, to lower intensity support in the community such as the provision of direct payments to arrange regular home care visits. Please provide answers on the attached and accompanying spreadsheet. 1. Please supply the name, email address and telephone number of the commissioner with responsibility for placements in supported living 2. Please provide the total number of adults (aged 18-64) with a primary support need of learning disabilities (LD) or Autism Spectrum Disorder (ASD) funded by the ICB/Health Board and receiving long-term care in supported living settings. Please provide data for the financial years 2021/22, 2022/23, 2023/24, 2024/25, 2025/26 and where possible projected figures for 2026/27 a. How many are placed in area (i.e. within the ICB/Health Board boundary)? b. How many are placed out of area (i.e. outside the ICB/Health Board boundary)? 3. Please provide a list of providers of supported living services used by the ICB/Health Board to place adults (aged 18-64) with a primary support need of LD or ASD receiving long-term care. To clarify, this does not include sole providers of accommodation, such as Housing Associations; only care providers registered to deliver personal care, and is only those providers registered as a care agency with the inspectorate. Please provide data for the latest month (if available); if not the last financial year 2025/26 – please state which timescale has been used for the data provided. a. Please provide, for each provider, the number of adults aged 18-64 with LD or ASD funded by the ICB/Health Board in long-term supported living placements b. Please provide total expenditure with each provider related to long-term placements in supported living for adults aged 18-64 with LD or ASD 4. Please provide the (a) highest, (b) lowest and (c) average weekly fee the ICB/Health Board pays to providers of long-term care in supported living settings for adults (aged 18-64) with LD or ASD. Please provide data for the latest month (if available); if not, the last financial year 2025/26 5. Please provide the number of adults (aged 18-64) with primary support need of LD or ASD in supported living with fees per week of: a. Less than £1,500 b. £1,500 to £2,999 c. £3,000 to £4,999 d. £5,000 to £6,999 e. £7,000 and more 6. Does the ICB/Health Board consider there is sufficient local supported living care provision to meet the needs of aged 18-64 with learning disabilities and/or autism and which providers does the ICB/Health Board mainly use for these placements? What are occupancy levels locally?
Date of Response: 25/09/2026
View Response: 11954.pdf
Freedom of Information Request Reference: 11943
Date Received: 21/09/2026
Summary:
Request in relation to medical records.
Date of Response: 21/09/2026
View Response: 11943.pdf
Freedom of Information Request Reference: 11908
Date Received: 10/09/2026
Summary:
NHS Lothian's role in overseeing the handback process and associated remedial works, you may be best placed to provide advice or direct me to the appropriate colleagues. In particular, I would be grateful for any information on: • Who is responsible for overseeing the handback process and associated remedial works. • What assurances are in place to ensure the required works are completed before handback. • Any background on why significant remedial works have been identified. • Any information that can be shared regarding governance, monitoring arrangements, or reported funding issues.
Date of Response: 24/09/2026
View Response: 11908.pdf
Freedom of Information Request Reference: 11907
Date Received: 10/09/2026
Summary:
I was wondering if it would be possible to obtain a list of email addresses for GP practices?
Date of Response: 25/09/2026
View Response: 11907.pdf
Freedom of Information Request Reference: 11898
Date Received: 08/09/2026
Summary:
I am writing to request information regarding active General Practices (GP practices) operating within your NHS Health Board region. Specifically, please provide a list containing the following details for each practice: - Practice Code - Practice Name - Practice Address and Postcode - Generic Practice Email Address (e.g., administrative, reception, or practice-level @nhs.scot / @nhs.net address) - Practice Manager Name - Practice Manager Email Address
Date of Response: 23/09/2026
View Response: 11898.pdf
Freedom of Information Request Reference: 11896
Date Received: 07/09/2026
Summary:
How many new patients were treated for any condition by the Trust's Dermatology and Rheumatology Department in the latest 3-month period of April, May and June 2026 (or the latest 3 months available) with the treatments I have provided below? Please can you define a "new patient" as a patient who is receiving any of the treatments listed below for the first time. If a patient received any of the below treatments in 2024 or previous years, they can be classed as a new patient for this period. Abatacept [Orencia] Adalimumab [Humira] Adalimumab [All Biosimilars] Apremilast [Generic] Apremilast [Otezla] Baricitinib [Olumiant] Bimekizumab [Bimzelx] Brodalumab [Kyntheum] Certolizumab [Cimzia] Deucravacitinib [Sotyktu] Dimethyl Fumarate [Skilarence] Etanercept [Enbrel] Etanercept [All Biosimilars] Filgotinib [Jyseleca] Golimumab [Simponi] Golimumab [All Biosimilars] Guselkumab [Tremfya] Infliximab [Remicade] Infliximab [All Biosimilars] Ixekizumab [Taltz] Risankizumab [Skyrizi] Rituximab [MabThera] Rituximab [Biosimilars] Sarilumab [Kevzara] Secukinumab [Cosentyx] Spesolimab [Spevigo] Tildrakizumab [illumetri] Tocilizumab [RoActemra] Tocilizumab [Biosimilars] Tofacitinib [Xeljanz] Upadacitinib [Rinvoq] Ustekinumab [Stelara] Ustekinumab [All Biosimilars]
Date of Response: 25/09/2026
View Response: 11896.pdf
Freedom of Information Request Reference: 11888
Date Received: 07/09/2026
Summary:
Please provide the following information, as of 7th September 2026 (or most recent): •For each Walk-in GP Clinic in your health board: 1) Has the Walk-in Clinic experienced an unexpected closure and, if so, on what dates? 2) If for part of a day, over what time period was the unexpected closure? 3) For each calendar month since the Walk-in Clinic was opened, what has been the total number of patient attendances resulting in a patient receiving a medical assessment by a) a GP or b) a nurse? 4) For each calendar month since the Walk-in Clinic was opened, what has been the highest number of patient attendances in a single day that resulted in a patient receiving a medical assessment by a) a GP or b) a nurse? 5) For each calendar month since the Walk-in Clinic was opened, what has been the lowest number of patient attendances in a single day that resulted in a patient receiving a medical assessment by a) a GP or b) a nurse? •For each unexpected closure of a Walk-in Clinic, what was the reason for the clinic to be closed?
Date of Response: 25/09/2026
View Response: 11888.pdf
Freedom of Information Request Reference: 11881
Date Received: 03/09/2026
Summary:
Request in relation to workforce systems.
Date of Response: 25/09/2026
View Response: 11881.pdf
Freedom of Information Request Reference: 11880
Date Received: 03/09/2026
Summary:
Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs: • Abatacept [Orencia] • Adalimumab [Humira] • Adalimumab Biosimilars • Apremilast [Otezla] • Apremilast [Generic] • Baricitinib [Olumiant] • Bimekizumab [Bimzelx] • Certolizumab [Cimzia] • Etanercept [Enbrel] • Etanercept Biosimilars • Filgotinib [Jyseleca] • Golimumab [Simponi] • Golimumab Biosimilar • Guselkumab [Tremfya] • Infliximab [Remicade] • Infliximab Biosimilars • Ixekizumab [Taltz] • Risankizumab [Skyrizi] • Rituximab [MabThera] • Rituximab Biosimilars • Sarilumab [Kevzara] • Secukinumab [Cosentyx] • Tocilizumab [Ro Actemra] • Tocilizumab Biosimilars • Tofacitinib [Xeljanz] • Upadacitinib [Rinvoq] • Ustekinumab [Stelara] • Ustekinumab Biosimilar
Date of Response: 24/09/2026
View Response: 11880.pdf
Freedom of Information Request Reference: 11877
Date Received: 03/09/2026
Summary:
Question One: How many patients has your trust treated in the past six months (for any disease) with the following drugs: Aubagio (teriflunomide) Avonex (interferon beta-1a) Betaferon (interferon beta-1b) Brabio (glatiramer acetate) Copaxone (glatiramer acetate) Extavia (beta interferon-1b) Gilenya (fingolimod) Kesimpta (ofatumumab) Lemtrada (alemtuzumab) Mavenclad (cladribine) Mayzent (siponimod) Ocrevus (ocrelizumab) Plegridy (peginterferon beta-1a) Ponvory (ponesimod) Rebif (beta interferon-1a) Tecfidera (dimethyl fumarate) Tysabri (natalizumab) Tysabri (natalizumab) Pre-filled syringes only Vumerity (diroximel fumarate) Zeposia (ozanimod) Fingolimod generic Tyruko (Natalizumab Biosimilar) Briumvi (ublituximab) Dimethyl fumarate generic Teriflunomide generic Question Two: How many patients has your trust treated with Rituximab for MS (Multiple Sclerosis) in the past six months? Question Three: How many patients within your trust have a diagnosis of MS (Multiple Sclerosis)?
Date of Response: 24/09/2026
View Response: 11877.pdf
Freedom of Information Request Reference: 11874
Date Received: 01/09/2026
Summary:
I'd like copies of the minutes of the meetings held to date ( August 2026) as referenced here - (item 4 progress update).
Date of Response: 24/09/2026
View Response: 11874.pdf
Freedom of Information Request Reference: 11873
Date Received: 01/09/2026
Summary:
How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs: • Adalimumab - Humira • Adalimumab Biosimilar • Apremilast - Otezla • Apremilast generic • Bimekizumab • Brodalumab • Certolizumab • Deucravacitinib • Dimethyl fumarate • Etanercept - Enbrel • Etanercept Biosimilar • Guselkumab • Infliximab - Remicade • Infliximab Biosimilar • Ixekizumab • Risankizumab • Secukinumab • Tildrakizumab • Ustekinumab - Stelara • Ustekinumab Biosimilar • Omalizumab • Spesolimab
Date of Response: 24/09/2026
View Response: 11873.pdf
Freedom of Information Request Reference: 11872
Date Received: 01/09/2026
Summary:
Now that the supplementary agreement has been agreed between NHS Lothian and Consort in relation to the RIE, please can you tell me how much money, to date, Consort has received to make up for the fact the Scottish government has mandated that parking should be free of charge at the RIE.
Date of Response: 18/09/2026
View Response: 11872.pdf
Freedom of Information Request Reference: 11871
Date Received: 01/09/2026
Summary:
Scanner Inventory • How many MRI scanners are used for prostate imaging at your Trust? (N): (For each scanner) • Manufacturer: • Scanner Model: • Scanner magnetic field strength (T): • What year was the scanner manufactured?: • What year was the scanner software last updated?: • Is this scanner a permanent or mobile unit?: • Is this scanner PIRADS v2.1 compliant?: • If ‘NO’, why is this scanner PIRADS v2.1 non-compliant? (Example: lack of high b-value (≥1,400 sec/mm2) image set): • Is an endorectal coil used with this scanner?: • If ‘YES’, please describe the endorectal coil used with this scanner (Example: DxTx Medical, eCoil): • Are any AI-based reconstruction or acquisition acceleration techniques used with this MRI scanner? (Example: No / Yes, vendor-provided / Yes, third-party AI software / Other): • If ‘Other’, please describe: • What is the full time slot that you dedicate to a multiparametric prostate MRI scan, including set-up, patient preparation time, imaging sequences, and patient turnaround? (X minutes): • What is the full time slot (minutes) that you dedicate to a biparametric prostate MRI scan, including set-up, patient preparation time, imaging sequences, and patient turnaround? (X minutes): Supplementary Imaging Techniques • Do you use an antispasmodic during prostate MRI imaging?: • If ‘YES’, please describe your antispasmodic drug, route of administration and dose (Example: Hyoscine butylbromide, intramuscular, 20mg): • Do you use any bowel preparation before prostate MRI imaging?: • If ‘YES’, please describe your method of bowel preparation (Example: Rectal enema): • Do you currently use an AI algorithm (commercial or academic) as part of your clinical workflow for prostate MRI reporting?: • If ‘YES’, please describe which algorithm(s) is currently being used (Example: Pi - Lucida Medical): Capacity • How many prostate MRIs were performed at the Trust in the last 3 months? • In the past 3 months, what proportion(%) of these scans were biparametric? • How many prostate MRIs were performed at the Trust in 2025? • In 2025, what proportion(%) of these scans were biparametric? • How many prostate MRIs were performed at the Trust in 2024? • In 2024, what proportion(%) of these scans were biparametric? • How many prostate MRIs were performed at the Trust in 2023? • In 2023, what proportion(%) of these scans were biparametric? Workforce • How many radiologists report prostate MRIs at your Trust? (N): (For each radiologist) • How many prostate MRIs does radiologist X report per year? • How many years of experience does radiologist X have in reporting prostate MRIs? Access • Based on the last 3 months, what is the mean wait time (days) for patients to receive an MRI having been referred onto the 2-week suspected prostate cancer pathway? (Duration from date of referral to date of scan in days): • Based on the last 3 months, what is the mean wait time (days) for prostate MRI interpretation by a radiologist? (Duration from date of scan to date of report in days):
Date of Response: 24/09/2026
View Response: 11871.pdf
Freedom of Information Request Reference: 11869
Date Received: 31/08/2026
Summary:
We would be very grateful if you could provide: • A copy/link to the paediatric sleep diary you currently use in your service • The usual duration and instructions for completion • Any available data on diary return rates • Whether you have looked at accuracy, reliability, or missing data • Any audits, evaluations or feedback concerning the diary used
Date of Response: 24/09/2026
View Response: 11869.pdf
Freedom of Information Request Reference: 11865
Date Received: 28/08/2026
Summary:
Please provide the current headcount and Whole Time Equivalent (WTE) of employees currently employed by NHS Lothian under Agenda for Change Band 8c, broken down by staff group/profession. And, please state how many employees currently employed by NHS Lothian on Agenda for Change Band 8c occupy job roles where the 'Knowledge, Training and Experience' job evaluation factor is matched at Level 8 (or doctoral equivalent). And, how many employees currently employed by NHS Lothian on Agenda for Change Band 8c with 'Knowledge, Training and Experience' job evaluation factor matched at Level 8 (or doctoral equivalent), do not hold a doctoral level qualification or equivalent? And, how many Band 8c evaluation outcomes were referred back to matching panels following mandatory consistency checking due to scoring anomalies, comparator issues, or equal pay considerations?
Date of Response: 21/09/2026
View Response: 11865.pdf
Freedom of Information Request Reference: 11864
Date Received: 31/08/2026
Summary:
I note that you have sent a report of theexternal cladding which answers my question as to its composition. However the other attachment is simply a BREEAM certificate. This appears to be an attempt to answer my question as to what the daylight factor is in the 4 bed rooms in the Childrtens Hospital. Only it doesn't answer the question. As explained the contract required a 3% daylight factor which is quite high. To achieve that you would need virtually a full width glazed external wall. However the Reference Design mandates a bed on the window wall which prevents this. As part of the B3 bid team I pointed this out. We even did a check which indicated one room would require the lights to be on in daylight hours. However we were advised that the room design was mandatory and that any departure from that layout would be at our risk. B3 therefore incorporated the layout into their bid in order to avoid disqualification. I was therefore interested to know how the winning bid kept the reference design layout whilst simultaneously achieving the 3% daylight factor demanded by the contract. Can I therefore ask you to review your response and provide an answer to that specific question? I suspect that Mott McDonald failed to address it as part of their assessment of the bids.
Date of Response: 25/09/2026
View Response: 11864.pdf
Freedom of Information Request Reference: 11861
Date Received: 28/08/2026
Summary:
Please send me the current Agenda for Change Matched Job Reports and current Job Descriptions and AFC Bands for the following NHS Lothian jobs: Nurse Director - Community Nursing Deputy Director of People & Culture - Human Resources Clinical Nurse Manager - Children's Services HR Manager - Job Evaluation Lead - Human Resources
Date of Response: 18/09/2026
View Response: 11861.pdf
Freedom of Information Request Reference: 11860
Date Received: 28/08/2026
Summary:
I would like to request information on software providers for these workforce management functions: • agency for nurses • agency for allied health professionals • agency for medics • job planning for allied health professionals For each of these, could you please provide: • the name of the current provider • the contract start and end dates, including any extension options • the annual contract spend • the number of licences contracted/purchased and count of licences used
Date of Response: 21/09/2026
View Response: 11860.pdf
Freedom of Information Request Reference: 11856
Date Received: 25/08/2026
Summary:
For financial years 2023/24, 2024/25, 2025/26 and 2026/27 to date, broken down by year: 1/ How many missed outpatient appointments were recorded by the NHS board? a/ Please break these appointments down by intended centre of attendance b/ Please also break these down by type of appointment (i.e. type of procedure being carried out) 2/ How many outpatient appointments were booked as a whole across the NHS board area? a/ Please also break these down by centre of attendance b/ Please also break these down by type of appointment (i.e. type of procedure being carried out) 3/ What is the average cost of a missed appointment to the board? How is this calculated?
Date of Response: 18/09/2026
View Response: 11856.pdf
Freedom of Information Request Reference: 11853
Date Received: 24/08/2026
Summary:
* Number of staff (headcount) working in each ward in the Acute Services Division of NHS Lothian (including maternity) * The number of Band 7 charge nurses/midwives with line management responsibility attached to each of the above wards
Date of Response: 25/09/2026
View Response: 11853.pdf
Freedom of Information Request Reference: 11844
Date Received: 19/08/2002
Summary:
I am emailing to request a review of the response you gave to Q2. I appreciate the information you provided answers Q1. but it does not clearly provide an answer to Q2. The question was: “Q2. Does your health board record the time from an admission for urinary retention in males (R.33X) to the point at which these patients undergo the following OPCS coded episodes of bladder outflow obstruction surgery? If it does, please confirm which of the OPCS coded surgeries it records this information for. Procedure Title Code(s) TURP M65.3 Monopolar and bipolar TURP M65.3 + Y10.2 Bladder Neck Incision (electrocautery) M66.2 + Y10.2 Bladder Neck Incision (Holmium laser) M66.2 +Y08.6 Holmium laser enucleation of prostate HoLEP M65.4 + Y05.6 Greenlight laser vaporisation (PVP) M65.4 + Y10.4 Rezum steam therapy M65.6 Urolift M68.3 Aqua ablation of prostate M65.8 Open prostatectomy (for benign disease) M61.- Could you please confirm if NHS Lothian does record the time from an admission for urinary retention in males (R.33X) to the point at which these patients undergo the OPCS coded episodes of bladder outflow obstruction surgery? The question also asks, if NHS Lothian does record this information, which of the listed coded surgeries does it record this for. Could you please confirm which of the specific coded surgeries NHS Lothian records this information for?
Date of Response: 25/09/2026
View Response: 11844.pdf
Freedom of Information Request Reference: 11830
Date Received: 14/08/2026
Summary:
1. On how many occasions in (a) 2020/21 b) 2021/22, c) 2022/23, d) 2023/24, e)2024/25 and f)2025/26 did your health board send scans to external radiology providers in (a) Scotland (b) the rest of the UK and (c) outside of the UK, for reporting services. 2. During the last three years, which countries outside of the UK has your health board sent scans for analysis to, broken down by the number of scans sent. 3. On how many occasions have staff reported concerns about the quality of reporting by companies sub-contracted to conduct radiology services. 4. Please provide me with the a) average and b) longest waiting time for patient to receive the results of a scan where it has been sent to an external radiology provider.
Date of Response: 18/09/2026
View Response: 11830.pdf
Freedom of Information Request Reference: 11809
Date Received: 06/08/2026
Summary:
Please provide: • The current annual salary of the Chief Executive. • Details of any additional remuneration, allowances, bonuses or benefits received in the most recent financial year.
Date of Response: 03/09/2026
View Response: 11809.pdf
Freedom of Information Request Reference: 11784
Date Received: 30/07/2026
Summary:
Please provide information held by Lothian Health Board / NHS Lothian concerning the protocol, policy, standard operating procedure, guidance, or equivalent document governing the performance and reporting of lower limb arterial duplex ultrasound scans. For this request, "lower limb arterial duplex scan" means a duplex ultrasound assessment of the arteries of the lower limb performed for vascular assessment, including but not limited to assessment for peripheral arterial disease, stenosis, occlusion, reduced flow, or related vascular pathology. Please provide the following information: 1. Current protocol or policy A copy of the current protocol, policy, standard operating procedure, guidance, or equivalent document used by NHS Lothian for performing lower limb arterial duplex scans. 2. Personnel performing the scan. Information confirming who is authorised or expected to perform lower limb arterial duplex scans, including whether scans are performed by: o vascular scientists; o sonographers; o radiologists; o vascular surgeons; o other clinicians or healthcare professionals. 3. Anatomical scope of the scan Information confirming which arteries are routinely assessed during a lower limb arterial duplex scan, including whether the scan protocol includes assessment of: o iliac arteries; o common femoral artery; o profunda femoris artery; o superficial femoral artery; o popliteal artery; o anterior tibial artery; o posterior tibial artery; o peroneal artery; o dorsalis pedis artery; o plantar arteries or other arteries of the foot. 4. Assessment of leg and foot arteries Please confirm whether arteries in both the leg and foot are routinely scanned and reported, and if not, please identify the circumstances in which foot arteries are included or excluded. 5. Reporting of findings Please provide information confirming whether the reporting protocol requires: o positive findings to be reported, including stenosis, occlusion, reduced flow, abnormal waveforms, or other pathology; o negative findings to be reported, including confirmation of normal flow, absence of stenosis, or absence of occlusion; o non-visualisation of any vessel to be reported; o limitations of the scan to be recorded. 6. Use of national clinical guidelines Please confirm whether the NHS Lothian protocol or policy follows, incorporates, or refers to any national clinical guidelines, professional standards, or other external guidance. If so, please identify the relevant guidelines or standards, including the version or date where held. 7. Changes in the past five years Please provide information confirming whether there have been any changes in the past five years to: o how lower limb arterial duplex scans are performed; o which vessels are assessed; o whether foot arteries are assessed; o how positive findings are reported; o how negative findings are reported; o the format or content of the scan report. 8. Previous versions of policies or protocols If the current protocol or policy has changed within the past five years, please provide copies of the previous versions, together with the dates on which they were in force, if held. 9. Report template or pro forma Please provide a copy of any standard reporting template, pro forma, structured report, checklist, or reporting guidance used for lower limb arterial duplex scans, including any previous versions used within the past five years, if held. If any of the requested information is held in separate departments, including radiology, vascular laboratory, vascular surgery, or medical physics, please treat this request as applying to all relevant departments within Lothian Health Board / NHS Lothian.
Date of Response: 18/09/2026
View Response: 11784.pdf
Freedom of Information Request Reference: 11772
Date Received: 28/07/2026
Summary:
Q1a. With regards to administration sets (pump and gravity) used to infuse IV antibiotics, does your institution have a policy to flush the administration set to give the full dose of antibiotics in accordance with the following guidelines? • The Royal Marsden Manual of Clinical Nursing Procedures, Tenth Edition, Chapter 15, which states: “After completion of an intermittent infusion, an appropriate diluent solution should be administered via the administration set. This is to ensure the full dose of medication has been administered to the patient.” • The “MEDUSA” injectable medicines guide instructions on how to administer intermittent infusions, which states: “Flush the administration set before it is disconnected with sufficient volume of sodium chloride (or compatible diluent) to ensure the total dose is given. Flush at the same rate the medicine was administered.” • The National Infusion and Vascular Access Society (NIVAS) “Intravenous Administration of Medicines to adults: “NIVAS Clinical Standards for Vascular Access & Infusion Therapy 2026”, which states: “Standard 22.6 IV giving sets must be flushed to ensure the residual medicine within the set is fully administered.” Q1b. If the answer to Q1a is “yes”, is your organisation fully compliant with your policy to flush the administration set to give the full dose of antibiotics in accordance with guidelines? Q1c. If the answer to Q1a is “yes”, do you follow the methodology outlined in the NIVAS guidelines linked above? Q2a. With regards to administration sets (pump and gravity) used to infuse IV antibiotics, if you do have a policy in place to flush the administration set, have you audited compliance with this policy? Q2b. If the answer to Q2a is “yes”, can you share the audit results? If so, please provide a copy as an attachment to your response to this FoIR. Q3. What education measures have you put in place to ensure healthcare professionals in your organisation understand: 1. The existing guidance on flushing administration sets that are used for IV antibiotic infusions (as laid out in the sources above)? 2. The patient risks involved with failing to flush the residual volume of IV antibiotics in the administration sets? 3. The possible effects of not flushing the IV administration set containing IV antibiotics on antimicrobial resistance? Q4. With regards to administration sets (pump and gravity) used to infuse IV antibiotics, which of the following (if any) are included in your policy with regards to disposing of the administration set and residual volume of either the prescribed antibiotic or flushing solution? 1. Complete administration set (including drip chamber with sharp) is disposed of into the yellow bag. 2. Complete administration set (including drip chamber with sharp) is disposed of into the orange bag. 3. Complete administration set (including drip chamber with sharp) is disposed of into the sharps bin. 4. Drip chamber/sharp are detached from the administration set line and the drip chamber/sharp disposed of in the sharps bin and the rest of the administration set line disposed of in the yellow bag. 5. Drip chamber/sharp is detached from the administration set line and the drip chamber/sharp disposed of in the sharps bin and the rest of the administration set line disposed of in the orange bag. 6. Other (please state)
Date of Response: 18/09/2026
View Response: 11772.pdf
Freedom of Information Request Reference: 11762
Date Received: 21/07/2026
Summary:
I would be grateful if you could confirm that your response considers all aspects of the steam gun machine including the hook which it is supposed to rest on. This hook is attached to the machine and I attach a photograph for your reference. I realise the wording of the FOI states “steam gun” and I just want to ensure that the entire machine has been considered and not just the actual gun/nozzle part.
Date of Response: 23/09/2026
View Response: 11762.pdf
Freedom of Information Request Reference: 11748
Date Received: 21/07/2026
Summary:
I am seeking anonymised data relating to Royal Infirmary of Edinburgh car park(s), covering the period 1 June 2024 to 30 June 2026 (or the most recent full month available): 1. The total revenue generated from parking fines/Parking Charge Notices (PCNs) issued at Royal Infirmary of Edinburgh, whether collected directly by NHS Lothian or by a third-party parking contractor operating on its behalf. Please provide this broken down by financial year (or by month, if held at that level of granularity). 2. Whether car park enforcement at Royal Infirmary of Edinburgh is managed in-house by the Trust or outsourced to a third-party contractor, and if outsourced, the name of that contractor. 3. The number of crime, safety, or security incidents logged in relation to Royal Infirmary of Edinburgh car park(s) during this period, broken down by category where recorded (e.g. theft of vehicle, theft from vehicle, criminal damage/vandalism, assault, anti-social behaviour), and broken down by month and year.
Date of Response: 25/09/2026
View Response: 11748.pdf
Freedom of Information Request Reference: 11735
Date Received: 17/07/2026
Summary:
I am writing to request a summary, through Freedom of Information legislation, of average waiting times from GP referral to initial assessment appointment for bipolar affective disorder within NHS Lothian. Specifically, this should be average times for non-emergency appointments (e.g. not presenting with active psychosis) and, if possible, I would also like to know specific timelines where a diagnosis is made of Bipolar Type 2. Finally, I would like to request information on available treatment pathways and support available for this condition within the same area - in further detail than that this is managed by NHS Lothian Psychological Therapies.
Date of Response: 18/09/2026
View Response: 11735.pdf
Freedom of Information Request Reference: 11720
Date Received: 14/07/2026
Summary:
1. Confirmation of what exactly the board’s Paediatric Neurodevelopmental Service does. I understand boards have this service that is considered separately to CAMHS. Please specify the patient age range it focuses on and the conditions it focuses on. 2. Confirmation of whether or not there is a standard wait target for children to begin receiving treatment/support from the board’s Paediatric Neurodevelopmental Service. In other words, is there a standard waiting time target that the health board tries to meet like they do with the CAMH’s 18 week target? 3. The longest recorded wait (in days or weeks) for a person to begin treatment/support from the Paediatric Neurodevelopmental Service. By longest wait I mean the longest wait (in days) that an individual had out of everyone who had waited to treatment/support Please provide the longest wait per year for the last six years (2021, 2022, 2023, 2024, 2025 and 2026). Please provide this information in a very clear way and state the number of weeks or days very clearly. For example a table that shows the longest wait per year and should allow someone see clearly that for example ‘the longest an individual waited in X year was Y days. Please also confirm if that person is still waiting or they have eventually started having the support. 4. The total number of people currently on a waiting list to access Paediatric Neurodevelopmental Service. If possible please also provide a breakdown of how many people within that number have been waiting (i) Over 1 year (ii) Over 2 years (iii) Over 3 years (iv) Over 4 years 5. The current average wait for a person to access the Paediatric Neurodevelopmental Service.
Date of Response: 24/09/2026
View Response: 11720.pdf
Freedom of Information Request Reference: 11714
Date Received: 14/07/2026
Summary:
Please provide the following information for each financial year from 2019/20 to 2025/26 (or most recent): 1. The number of compensation payouts made. 2. Please specify whether each payout was made to an employee of your health board or to a member of the public receiving care from your health board. Where the payout was made to an employee, please provide the employee’s job title, including but not limited to doctor, nurse, cleaner or executive. 3. Please specify the amount of compensation paid in each case, in pounds sterling, and provide the total amount paid across all cases during the overall time period. 4. Please specify the reason for the compensation paid in each case, such as vehicle accident claims, employer liability and employment tribunal claims, public liability claims, or other relevant categories.
Date of Response: 14/09/2026
View Response: 11714.pdf
Freedom of Information Request Reference: 11711
Date Received: 14/07/2026
Summary:
Please provide the following information under the Freedom of Information Act for the most recent 24 month period (or most recent available): • Total usage (units/ampoules) of acetylcholine chloride for intraocular irrigation. • A breakdown of usage by product, including: - MIPHTEL 20mg - Any other branded or unbranded acetylcholine chloride products • How many units of MIPHTEL were purchased/used, and from which suppliers (e.g., AAH, Alliance, Healthnet Homecare, Nordic Pharma). • Details of any alternative products used for intraoperative miosis when acetylcholine chloride is required. • Whether the Trust uses or sources any generic versions of acetylcholine chloride; if so, please provide product name, supplier, and usage. • Any supply issues experienced with MIPHTEL or acetylcholine chloride in the last 24 months. • Please can you provide the email and the named person for pharmacy Procurement
Date of Response: 21/09/2026
View Response: 11711.pdf
Freedom of Information Request Reference: 11653
Date Received: 01/07/2026
Summary:
Number of neurodevelopmental assessments undertaken on adults by NHS Lothian per year since 2020.
Date of Response: 22/09/2026
View Response: 11653.pdf
Freedom of Information Request Reference: 11652
Date Received: 01/07/2026
Summary:
Number of ADHD assessments undertaken by NHS Lothian per year since 2020.
Date of Response: 22/09/2026
View Response: 11652.pdf
Freedom of Information Request Reference: 11600
Date Received: 18/06/2026
Summary:
I am requesting the following information relating to the Adult Neurodevelopmental Service in NHS Lothian, preferably broken down by area where possible. i.e West Lothian, East Lothian etc. 1. Waiting List Validation Please provide: a) The number of patients contacted as part of the waiting list validation exercise since its commencement. b) The number of patients who confirmed that they wished to remain on the waiting list. c) The number of patients removed from the waiting list following validation. d) The number of patients removed due to non-response. e) The number of patients removed for any other reason following validation. f) Copies of any current policy, procedure, protocol, guidance, standard operating procedure, business rules or work instructions used in relation to the waiting list validation exercise. 2. Waiting List Position Please provide: a) The referral month and year currently being offered routine first assessment appointments. b) The referral month and year of the oldest patient currently awaiting a routine first assessment. c) The number of patients currently awaiting a first assessment, broken down by referral year: • 2020 • 2021 • 2022 • 2023 • 2024 • 2025 • 2026 d) The number of patients currently waiting longer than: • 52 weeks • 104 weeks • 156 weeks • 208 weeks • 260 weeks 3. Assessment Activity and Referrals For each of the following financial years: • 2023/24 • 2024/25 • 2025/26 please provide: a) The number of new referrals received. b) The number of first neurodevelopmental assessments completed. c) The opening waiting list size. d) The closing waiting list size. e) The number of patients removed from the waiting list for reasons other than completion of a first assessment. 4. Staffing Please provide the whole-time equivalent staffing levels undertaking adult neurodevelopmental assessments as at: • 31 March 2024 • 31 March 2025 • 31 March 2026 Please provide the figures by staff group where recorded. 5. Referral Order Please provide: a) Any policy, procedure, guidance, operational document or business rules describing how routine referrals are offered appointments in referral-date order. b) Details of any circumstances in which a routine referral may be offered an appointment ahead of an earlier routine referral. 6. Service Recovery and Performance Monitoring Please provide copies of any waiting list recovery plans, backlog reduction plans, capacity plans, business cases, briefing papers, performance reports or dashboards produced since 1 January 2025 that relate to: • Adult neurodevelopmental waiting lists • Waiting times • Waiting list validation • Capacity planning • Backlog reduction • Service recovery
Date of Response: 18/09/2026
View Response: 11600.pdf
Freedom of Information Request Reference: 11400
Date Received: 17/04/2026
Summary:
Please provide data from the following financial years: 2020/21, 2021/22, 2022/23, 2023/24, 2024/25 and 2025/26. Heading 1 - Access & Timelines 1. Median Wait 2. 90th Percentile Wait 3. Waiting List Size (Snapshot as of 31st March for each respective year) 4. Wait > 18 Weeks 5. Wait > 52 Weeks 6. Referral Rejection/Redirect Rate Heading 2 - The Workforce (Stability & Burnout) 1. Funded Substantive Consultant Posts (WTE) 2. Vacant Substantive Posts (WTE) 3. Total expenditure on agency/locum doctors specifically for GAP rotas 4. Locum Consultant Usage (WTE) 5. Consultant Sickness Absence Rate (%): Specifically for GAP consultants 6. Staff Turnover Rate (%) Heading 3 - The CMHT Caseload (Workload) 1. Active Caseload per Consultant (WTE) 2. Active Caseload per CPN (WTE) - i.e., Total GAP Caseload / Total WTE of Band 5/6 Community Psychiatric Nurses 3. Number of Patients on Care Programme Approach (CPA) Heading 4 - The Inpatient Ward (Safety & Flow) 1. Staffed Acute GAP Beds Available 2. Average Bed Occupancy (%) 3. Delayed Discharges - Number of patients in acute GAP beds medically fit for discharge awaiting community care package. 4. Out of Area Placements 5. Readmission within 28 Days (%) Heading 5 - The Safety Net (Legal & Crisis) 1. Number of Emergency Detention Certificates (EDCs) 2. Use of Mental Health Act: Number of Short-Term Detention Certificates (STDCs) issued. 3. Incidents of Self-Harm/Suicide: Specifically for patients known to GAP services. 4. Outpatient DNA Rate (%): Percentage of patients who Did Not Attend their GAP appointment.
Date of Response: 18/09/2026
View Response: 11400.pdf
Freedom of Information Request Reference: 11868
Date Received: 31/08/2026
Summary:
Request in relation to data on Housing Adaptations Across All Tenure Types.
Date of Response: 16/09/2026
View Response: 11868.pdf
Freedom of Information Request Reference: 11867
Date Received: 28/08/2026
Summary:
Please could you provide the product name and supplier name for the following software systems currently used by the Board: • EPR - Electronic Patient Record • PAS - Patient Administration System • Integration Engine / Interface Engine • ePMA - Electronic Prescribing and Medicines Administration • MIS - Maternity Information System • LIMS - Laboratory Information Management System • RIS - Radiology Information System • PACS - Picture Archiving and Communication System • Emergency Department / Urgent Care System • Patient Portal • Data Warehouse / BI / Analytics Platform • IAM / SSO - Identity, Access Management and Single Sign-On • EDMS - Electronic Document Management System • AVT - Ambient Voice Technology • Virtual Ward / Remote Patient Monitoring Platform
Date of Response: 14/09/2026
View Response: 11867.pdf
Freedom of Information Request Reference: 11862
Date Received: 28/08/2026
Summary:
Question 1: For the Neurodevelopmental Adult NW team, please provide the total number of patients on the waiting list for an adult ADHD assessment for each year from 2023 to the present date (August 2026, or the latest available date). Please provide a separate figure for each calendar year (2023, 2024, 2025, and 2026 to date). Question 2: Please provide the current number of clinicians working within the North West Locality who are qualified to diagnose ADHD in adults.
Date of Response: 14/09/2026
View Response: 11862.pdf
Freedom of Information Request Reference: 11857
Date Received: 25/08/2026
Summary:
I am seeking recorded information about NHS services available to neurodivergent children and young people aged under 18 within your Health Board area. For this request, “neurodivergent” should be interpreted broadly and should include, but not be limited to, autism and ADHD. Please provide the following information as at the date of this request. 1. Neurodevelopmental services Please identify each NHS service or pathway provided or commissioned by the Health Board specifically for neurodivergent children and young people aged under 18. For each service/pathway, please provide, where recorded: • service/pathway name; • age range; • neurodevelopmental conditions or needs supported; • whether a formal diagnosis is required; • eligibility criteria; • referral route; • geographical restrictions; and • the responsible department or directorate. 2. CAMHS and neurodivergence Please identify any CAMHS team, pathway or provision specifically intended or adapted for neurodivergent children and young people. For each, please state whether the Board records the availability of staff with a specific specialist role, qualification or remit relating to autism, ADHD or neurodivergence. I am not requesting staff names or personal information. 3. Sexual abuse, sexual assault and significant trauma Please identify any service provided or commissioned by the Board which supports children and young people aged under 18 who have experienced: • sexual abuse; • sexual assault or sexual violence; • peer-on-peer sexual abuse; or • significant psychological trauma. For each service, please provide: • service/provider name; • age range; • eligibility criteria; • referral route; • geographical restrictions; • whether the service is NHS-operated or externally commissioned; and • where externally commissioned, the provider and current contract/funding period. 4. Neurodivergent children who have experienced sexual abuse or trauma Please identify any service, pathway, protocol or commissioning arrangement specifically addressing the needs of neurodivergent children or young people who have experienced sexual abuse, sexual violence or significant trauma. Please state whether the Board has any specifically commissioned or designated clinical expertise addressing the combination of neurodivergence and psychological/sexual trauma. 5. Children unable or not ready to give a detailed verbal account For services identified under questions 3 or 4, please provide any recorded: • policy; • clinical guidance; • referral criteria; • service specification; • pathway document; or • commissioning requirement which addresses children or young people who, because of neurodivergence, communication differences, developmental needs or trauma, are unable or not yet ready to provide a detailed verbal account of what has happened to them. In particular, please state whether such a child can access assessment, relationship-building, stabilisation or therapeutic support without first being required to provide a detailed verbal disclosure or narrative of the traumatic event. If no recorded policy or provision addressing this is held, please state that. 6. Alternative and adapted communication Please identify any recorded provision within the services covered by questions 3–5 for: • non-verbal or reduced-verbal communication; • written or text-based communication; • visual communication; • augmentative or alternative communication; • sensory/environmental adaptations; • additional processing time; • predictable or structured therapeutic environments; or • other reasonable adaptations for neurodivergent children. 7. Referral outcomes Where centrally recorded and capable of being provided without reviewing individual patient records, please provide for the most recent 12-month period available: • number of under-18 referrals to the services identified under questions 3 and 4; • number accepted; • number declined or redirected; and • any centrally recorded categories/reasons for declined or redirected referrals. If the Board records “unable to engage”, “not ready”, “unable to disclose”, communication difficulties or similar reasons, please provide those categories and the corresponding aggregate numbers. I am not requesting patient-level information. 8. Waiting lists For each service identified under questions 1, 3 and 4, please provide the most recent centrally recorded: • number of children/young people waiting; and • average or median waiting time, where held. 9. Commissioned third-sector provision Please identify any charity, third-sector organisation or external provider currently funded or commissioned by the Health Board to provide: • neurodevelopmental support to children; • child sexual-abuse/sexual-violence support; • child trauma support; or • services addressing both neurodivergence and trauma. For each, please provide the service/provider, purpose of the commission, age range, current annual contract or funding value where recorded, and contract/funding period. 10. Policies, service specifications and rights assessments Please provide copies of, or links to, any current: • neurodevelopmental strategy or pathway; • child trauma/sexual-abuse pathway; • relevant service specification; • equality impact assessment; • children's rights or UNCRC assessment; or • needs assessment which addresses any of the services covered by this request. Where any document specifically considers neurodivergent children who have experienced abuse or trauma, please identify it.
Date of Response: 14/09/2026
View Response: 11857.pdf
Freedom of Information Request Reference: 11854
Date Received: 24/08/2026
Summary:
1. Please supply the name, job title, telephone number and email address of the commissioner with responsibility for mental health placements for adults aged 18 to 64, covering residential, nursing and supported living. 2. Please provide the total number of adults aged 18 to 64 with a primary diagnosis of mental health funded by the Health Board in long-term care – residential care, nursing care and supported living separately. Please give an end-of-year snapshot (at 31 March) for each of 2022/23, 2023/24, 2024/25 and 2025/26, and the most up-to-date figure available for 2026/27. 3. Please provide the number of new long-term placements made for adults aged 18 to 64 with a mental health need – residential care, nursing care and supported living separately. Please give the number during 2025/26 (year to 31 March 2026) and during 2026/27 to date. 4. Please provide the highest, lowest and average weekly rate paid for placements for adults aged 18 to 64 with a mental health need – residential care, nursing care and supported living separately – for 2026/27 or the latest year available, together with the average for 2025/26 for comparison. For supported living, please give the care and support fee only, excluding rent and housing costs, and please state the average hourly rate if care and support is commissioned by the hour. If you use weekly rate bands, please give these too. 5. Please provide a list of providers of residential care, nursing care and supported living used by the Health Board for adults aged 18 to 64 with a mental health need. For each provider, please give the setting (residential, nursing or supported living), the number of service users, and the gross expenditure, using the latest month available (or financial year 2025/26 if not), and state the month used.
Date of Response: 11/09/2026
View Response: 11854.pdf
Freedom of Information Request Reference: 11852
Date Received: 21/08/2026
Summary:
For each site the Board operates, please provide: 1. Designated disabled parking bays — the number, and the location of each: which car park, and grid reference, latitude/longitude or postcode if held. 2. Accessible toilets — the location of wheelchair-accessible toilets, by building, floor and department, and whether each needs a RADAR key. 3. Changing Places toilets — whether the Board has a facility meeting BS 8300, where it is, and its opening arrangements. 4. Step-free entrances and accessible drop-off — which entrances are step-free, and where any designated accessible drop-off point is.
Date of Response: 11/09/2026
View Response: 11852.pdf
Freedom of Information Request Reference: 11851
Date Received: 13/08/2026
Summary:
I would be grateful if you could provide: 1. An explanation of the PSB process and its intended purpose. 2. Details of the response timescales currently applied to patients receiving appointment booking correspondence. 3. The rationale and evidence supporting those timescales. 4. An explanation of the specific operational problem or objective that this process is intended to address, and how NHS Lothian measures whether it is achieving that objective. 5. Details of any equality, accessibility or patient experience considerations that informed the design of the process. 6. An explanation of why appointments staff are unable to exercise discretion where a patient makes contact shortly after a deadline has expired. 7. Information on how NHS Lothian monitors the impact of this process on patient access and patient experience. 8. Confirmation of whether NHS Lothian has reviewed the effectiveness of this process and, if so, the outcome of any such review. I would also be interested to understand: • How many working days patients are actually given to respond before being removed from the booking pathway. • Whether any audit has been undertaken regarding the number of patients who fail to respond within the timescale. • Whether NHS Lothian has assessed whether the process disproportionately affects particular patient groups.
Date of Response: 10/09/2026
View Response: 11851.pdf
Freedom of Information Request Reference: 11849
Date Received: 20/08/2026
Summary:
• Spend on Insourcing from May 2026-end of July 2026, broken down by each specialty and subspecialty, and the insourcing company that was used, e.g. cardiology £1000- echo cardiogram £1000- company x £1000 • The budget for each specialty for insourcing • Confirm the contract start and end date for each specialty • What frameworks were used for each specialty and was there direct awards and if so, who was they awarded to and what specialty • What was the service, e.g. theatres, outpatient, or diagnostic
Date of Response: 10/09/2026
View Response: 11849.pdf
Freedom of Information Request Reference: 11848
Date Received: 20/08/2026
Summary:
I am making a request under the Freedom of Information (Scotland) Act 2002 concerning the Scottish Specialist Prosthetics Service (SSPS) and the provision of specialist prosthetic foot and ankle technology. Published information concerning the Scottish Specialist Prosthetics Service refers to specialist foot and ankle joints and self-aligning ankle-feet. I would therefore be grateful for the following existing recorded information. 1. Current eligibility and prescribing criteria Please provide the current SSPS clinical eligibility and prescription criteria for: • specialist foot and ankle joints; • self-aligning ankle-feet; • hydraulic ankle-foot systems; • microprocessor-controlled ankle-foot systems; • powered or electronically controlled ankle-foot systems. 2. Devices available through SSPS Please provide the current list, formulary, prescribing matrix or schedule of ankle-foot devices which may be funded or supplied through SSPS. In particular, please provide the recorded status of: • Blatchford Elan / ElanIC; • Blatchford Echelon; • Blatchford Echelon VT; • Ottobock Meridium; • Ottobock Empower; • Össur Proprio Foot; • any other microprocessor-controlled, powered, electronically controlled or self-adjusting ankle-foot system. Please indicate, where recorded, whether each is: • routinely available; • available subject to clinical criteria; • restricted; • exceptional funding only; • available for clinical trial; • or not available. 3. Devices actually provided For each of the following financial years, please provide the number of devices approved, funded or supplied through SSPS, broken down by model where this information is held: • 2023/24; • 2024/25; • 2025/26; • 2026/27 to the date of this request. In particular, please provide figures for: • Elan / ElanIC; • Meridium; • Empower; • Proprio Foot; • Echelon / Echelon VT; • other advanced electronic or microprocessor ankle-foot systems. No patient-identifiable information is requested. 4. Applications and outcomes Please provide the number of applications or referrals for specialist ankle-foot technology during the above periods which were: • approved; • declined; • deferred for further assessment; • approved following a clinical trial. 5. Clinical criteria Please provide any written criteria used when considering a patient for specialist ankle-foot technology, including any recorded consideration of: • bilateral lower-limb amputation; • falls risk; • slopes, stairs and uneven terrain; • restricted knee function or other joint impairment; • pain or abnormal joint loading; • energy expenditure; • community mobility; • employment or occupational requirements; • rehabilitation potential. 6. Component trials Please provide any current policy concerning clinical trials of advanced prosthetic ankle-foot components, including: • manufacturer demonstration devices; • loan components; • comparative component trials; • trials prior to a final funding decision. 7. Financial criteria Please provide any: • financial threshold; • price ceiling; • additional approval procedure; • exceptional funding mechanism applicable to specialist ankle-foot prescriptions. 8. Reviews of advanced ankle technology Please provide copies of any product evaluations, technology reviews, committee papers, formulary reviews or policy reviews produced since 1 April 2023 concerning: • Elan / ElanIC; • Meridium; • Empower; • Proprio Foot; • microprocessor ankle-foot systems generally; • powered ankle-foot systems; • self-aligning ankle-feet. 9. Referral and cross-border access Please provide the current referral pathway to the Scottish Specialist Prosthetics Service, including: • which clinicians may refer; • whether referral must originate from a Scottish prosthetic centre; • residency requirements; • whether cross-border NHS referrals from England, Wales or Northern Ireland can be accepted; • whether a patient ordinarily resident in England can be assessed or treated by SSPS where their English NHS commissioner agrees to fund the assessment or treatment. 10. Which organisation holds the information? Where different elements of this request are held separately by: • NHS National Services Scotland; • WestMARC / NHS Greater Glasgow and Clyde; • SMART / NHS Lothian,
Date of Response: 11/09/2026
View Response: 11848.pdf
Freedom of Information Request Reference: 11846
Date Received: 20/08/2026
Summary:
I note that the West Lothian Chief Nurse Matched Job Report states, under factor 2. Knowledge, Training and Experience, that the applicant should have "advanced theoretical and practical knowledge, professional knowledge acquired through degree /diploma supplemented by specialist training, experience, short courses to doctorate level or equivalent". (See attached Matched Job Description). Doctorate level is SCQF Level 12. How does the post holder evidence that they have KTE to doctorate level/SCQF Level 12. Which SCQF Level 12 courses would evidence KTE at Level 8. SCPHN Specialist School Nurses can easily demonstrate that they have a Masters Level/SCQF Level 11 qualification (it's on the certificate) yet it's not clear how NHS Lothian Chief Nurses prove that they have knowledge, training and skills at PhD level/ SCQF Level 12. Please explain this inconsistency to me and tell me which SCQF Level 12 short courses are required for the post.
Date of Response: 11/09/2026
View Response: 11846.pdf
Freedom of Information Request Reference: 11845
Date Received: 20/08/2026
Summary:
Under freedom of information please can you provide all materials your health board has provided to staff which refers to first cousin marriage. This should include any guidelines or advice provided to NHS staff in your board area regarding first cousin marriage and any health implications for future children. This should also include any training materials provided to NHS staff in your health board area which covers the subject of first cousin marriage and any health implications for future children.
Date of Response: 11/09/2026
View Response: 11845.pdf
Freedom of Information Request Reference: 11843
Date Received: 19/08/2026
Summary:
I wish to appeal response 11629. You claim you cannot provide me with information because corridor care is not practised at St Johns Hospital. I did not ask if it is practised, I asked if it has occurred and that’s a very different thing. No hospital wants it to happen and no hospital would claim it’s practised but I believe across the country many doctors and nurses have acknowledged that due to sheer necessity patients have at some points been cared for in unconventional and sometimes inappropriate settings. I find it hard to believe that have never been any concerns raised about a single instance of this happening. I would like to request that you look again and check in each leader of staff’s inbox to make sure that corridor care of any kind hasn’t ben raised.
Date of Response: 16/09/2026
View Response: 11843.pdf
Freedom of Information Request Reference: 11842
Date Received: 19/08/2026
Summary:
I wish to appeal FOI response 11694. Every other health board has happily provided what I asked for. If you insist that what I have asked for makes a person 'identifiable' then please explain in detail why that is the case. I don't understand how revealing that an individual waited for example 66 weeks to start treatment identifies them in anyway? Who could possibly know that information about someone other than the person themself and some of their family members? I would suggest you reconsider your reason for not fulfilling my request. No other board agrees with your rationale and clearly have no fears about data making patients identifiable. As I have already said, if you believe it can identify someone then explain to me in detail why that's the case - don't just assert it.
Date of Response: 16/09/2026
View Response: 11842.pdf
Freedom of Information Request Reference: 11841
Date Received: 19/08/2026
Summary:
Request in relation to CCTV footage.
Date of Response: 07/09/2026
View Response: 11841.pdf
Freedom of Information Request Reference: 11840
Date Received: 19/08/2026
Summary:
Can you please tell me how many consultant doctors work full time and how many doctors work part time in each department I e cardiology,,vascular , orthopaedics and so on?
Date of Response: 11/09/2026
View Response: 11840.pdf
Freedom of Information Request Reference: 11839
Date Received: 19/08/2026
Summary:
For each financial year from 2019/20 to 2026/27 (most recent): 1. the total number of referrals for a Vasectomy 2. the median completed wait (in days) for a Vasectomy 3. the longest completed waited (in days) for a Vasectomy 4. the median ongoing wait (in days) for a Vasectomy 5. the longest ongoing wait (in days) for a Vasectomy
Date of Response: 10/09/2026
View Response: 11839.pdf
Freedom of Information Request Reference: 11836
Date Received: 17/08/2026
Summary:
Please provide recorded data regarding patient attendances and recorded presentations across your Health Board area over the past 10 calendar years (from 1 January 2016 to 31 December 2025, plus the available year-to-date figures for 2026). 1. Scope of Data Requested Please provide the annual counts/incidences (broken down by calendar year, individual hospital site/A&E department, and, where recorded, local GP practice cluster/postcode sector) for patient attendances/presentations associated with each of the following conditions: 1. Migraines (including ICD-10 G43 or relevant presenting complaint / Read / SNOMED codes) 2. Headaches (including ICD-10 R51 or equivalent) 3. Nausea and vomiting (including ICD-10 R11 or equivalent) 4. Balance problems / Vertigo / Dizziness (including ICD-10 R42, H81 or equivalent) 5. Depression (including ICD-10 F32, F33 or equivalent) 6. Sleep deprivation / Insomnia / Sleep disorders (including ICD-10 G47, F51 or equivalent) 7. Skin conditions (including ICD-10 L00–L99 or equivalent) 8. Cardiac conditions (including ICD-10 I00–I52, I20–I25 or equivalent) 9. Respiratory conditions (including ICD-10 J00–J99, J45 or equivalent) 10. Mental health presentations / referrals 11. Referrals to secondary physical or psychological healthcare services arising from the above presentations.
Date of Response: 10/09/2026
View Response: 11836.pdf
Freedom of Information Request Reference: 11835
Date Received: 17/08/2026
Summary:
Please provide the following information, as of 1 August 2026 (or most recent) 1) How many staff are currently employed on a full-time basis in GP walk-in clinics, broken down by (a) GP, (b) nurse and (c) administration and other staff. 2) By headcount, how many staff are currently employed in GP walk-in clinics, broken down by (a) GP, (b) nurse and (c) administration and other staff. 3) By FTE (full time equivalent), how many staff are currently employed in GP walk-in clinics, broken down by (a) GP, (b) nurse and (c) administration and other staff.
Date of Response: 11/09/2026
View Response: 11835.pdf
Freedom of Information Request Reference: 11834
Date Received: 17/08/2026
Summary:
Q1. Over the past 6 months, how many adult multiple myeloma [MM] patients have you treated? If you refer your multiple myeloma patients to another centre, please state which. Q2. Of the multiple myeloma patients over the past 6 months, how many were treated with the following: • Belantamab Mafodotin [Blenrep] • Belantamab Mafodotin [Blenrep] + Bortezomib [Velcade] + Dexamethasone • Belantamab Mafodotin [Blenrep] + Pomalidomide [Imnovid] + Dexamethasone • Bortezomib [Velcade] • Bortezomib [Velcade] + Dexamethasone • Bortezomib [Velcade] + Melphalan + Prednisolone/Dexamethasone (VMp or VCd) • Bortezomib [Velcade] + Thalidomide + Dexamethasone (VTD) • Carfilzomib [Kyprolis] + Dexamethasone • Carfilzomib [Kyprolis] + Lenalidomide [Revlimid] + Dexamethasone (KRd) • Daratumumab [Darzalex] + Bortezomib [Velcade] + Dexamethasone (DVd/DBd) • Daratumumab [Darzalex] + Bortezomib [Velcade] + Thalidomide + Dexamethasone (Dara-VTd) • Daratumumab [Darzalex] + Lenalidomide [Revlimid] + Dexamethasone (DRd) • Daratumumab [Darzalex] monotherapy • Elranatamab • Idecabtagene vicleucel [Abecma] • Isatuximab [Sarclisa] subcutaneous injection + Bortezomib [Velcade] + Lenalidomide [Revlimid] + Dexamethasone (Isa-VRd) • Isatuximab [Sarclisa] + Pomalidomide [Imnovid] + Dexamethasone (IsaPd) • Ixazomib [Ninlaro] + Lenalidomide [Revlimid] + Dexamethasone (IRd) • Lenalidomide [Revlimid] + Dexamethasone • Lenalidomide [Revlimid] monotherapy • Panobinostat + Bortezomib + Dexamethasone • Pomalidomide [Imnovid] + Dexamethasone • Selinexor + Bortezomib [Velcade] + Dexamethasone • Selinexor + Dexamethasone • Talquetamab • Teclistamab [Tecvayli] • Any other systemic anti-cancer therapy for Multiple Myeloma Only [please specify] Q3. In the last 6 months, how many patients have been initiated* on the following regimens? • Belantamab Mafodotin [Blenrep] + Bortezomib [Velcade] + Dexamethasone • Belantamab Mafodotin [Blenrep] + Pomalidomide [Imnovid] + Dexamethasone • Bortezomib [Velcade] + Thalidomide + Dexamethasone (VTD) • Carfilzomib [Kyprolis] + Dexamethasone • Carfilzomib [Kyprolis] + Lenalidomide [Revlimid] + Dexamethasone (KRd) • Daratumumab [Darzalex] + Bortezomib [Velcade] + Dexamethasone (DVd/DBd) • Daratumumab [Darzalex] + Bortezomib [Velcade] + Thalidomide + Dexamethasone (Dara-VTd) • Daratumumab [Darzalex] + Lenalidomide [Revlimid] + Dexamethasone (DRd) • Isatuximab [Sarclisa] subcutaneous injection + Bortezomib [Velcade] + Lenalidomide [Revlimid] + Dexamethasone (Isa-VRd) • Lenalidomide [Revlimid] monotherapy • Lenalidomide [Revlimid] + Dexamethasone • Selinexor + Bortezomib [Velcade] + Dexamethasone • Selinexor + Dexamethasone • Any other systemic anti-cancer therapy for Multiple Myeloma Only [please specify] *Patients are considered initiated if they have not received any of the drugs in the named regimen (either alone or in combination) in the 6 months prior to initiation. Q4. In the last 6 months, how many patients have received the following second-line treatment? • Lenalidomide [Revlimid] + Dexamethasone Q5. Does your trust participate in any clinical trials for multiple myeloma? If so, please provide the name of each trial, and the number of patients taking part.
Date of Response: 10/09/2026
View Response: 11834.pdf
Freedom of Information Request Reference: 11831
Date Received: 17/08/2026
Summary:
1. How many referrals have been made to CAMHS from GP for primary school aged children in each of the years 2022/23/24/25 & 26 so far? 2. Of these referrals, how many were not accepted by CAMHS and referred back to primary care (GP)? 3. How many referrals to CAMHS were made from GP for secondary school aged children in the years 2022/23/24/25 and 26 so far? 4. Of these referrals, how many were not accepted by CAMHS and referred back to primary care? 5. Of the referrals that were accepted, what was the average number of appointments with were attended prior to being discharged?
Date of Response: 10/09/2026
View Response: 11831.pdf
Carer Positive Icon
Awards Aware Icon
We are a Living wage Employer Icon
Duke of Edinburgh's Award Logo
Young Person's Guaranteed Employer Logo
Scottish Top Employers Logo
Disability Confident Employer Logo
 
CONTACT NHS LOTHIAN
Lothian NHS Board
Waverley Court
4 East Market Street
Edinburgh
EH8 8BG

Main Switchboard: 0131 242 1000
YOUR RIGHTS
OUR VALUES INTO ACTION
Around 3,000 colleagues across NHS Lothian have developed Our Values, a set of common values and ways of working - to the benefit of everyone working in the organisation and, most importantly - to the benefit of our patients.
WORKING WITH NHS LOTHIAN
MEDIA ENQUIRIES
STAY CONNECTED TO NHS LOTHIAN
Facebook
Twitter
YouTube
Vimeo
Instagram
PARTNERS
NHS Lothian Charity Logo
Tel: +44 (0)131 465 5850
Email: loth.charity@nhs.scot

Scottish Registered Charity No: SC007342
The official charity of NHS Lothian.
From the everyday to the transformational, we support NHS Lothian to excel for all the communities it serves: patients, families, carers and staff.
Making healthcare better, together.
Find out more about NHS Lothian Charity
Donate